Synthetic Studies directed towards Asmarines by Kania, Jindrich
 Synthetic Studies directed towards 
Asmarines 
 
Dissertation for the degree of Ph.D. 
 
Jindrich Kania 
 
 
 
 
 
Faculty of Mathematics and Natural Sciences 
 
 
University of Oslo 
 
2013 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Jindrich Kania, 2013 
 
 
Series of dissertations submitted to the  
Faculty of Mathematics and Natural Sciences, University of Oslo 
No. 1342 
 
ISSN 1501-7710 
 
 
All rights reserved. No part of this publication may be  
reproduced or transmitted, in any form or by any means, without permission.   
 
 
 
 
 
 
 
 
Cover: Inger Sandved Anfinsen. 
Printed in Norway: AIT Oslo AS.   
 
Produced in co-operation with Akademika publishing.  
The thesis is produced by Akademika publishing merely in connection with the  
thesis defence. Kindly direct all inquiries regarding the thesis to the copyright  
holder or the unit which grants the doctorate.   
i 
 
 
 
  
to Petra 
ii 
 
Acknowledgments 
During my studies here at the University of Oslo, I have attended several PhD defences. From 
this experience I learned that the acknowledgments section is a very important part of the 
thesis, because most of the future readers will pay attention especially to this section. 
Therefore, I would like to use this opportunity to encourage everyone who is reading these 
lines to continue reading through the whole work.  
 
The work presented in this thesis has been carried out at the Department of Chemistry, 
University of Oslo, during the period November 2008 – July 2012. The Research Council of 
Norway (KOSK II project number 143135), NordForsk network Excellent Nordic Chemistry 
and S. G. Sønneland Foundation are acknowledged for the financial support. 
 
First of all I wish to thank to my supervisor, professor Lise-Lotte Gundersen, for giving me a 
chance to come to Norway and participate on this scientific work. Thanks for all the 
discussions we had. I learned a lot here and the experience from this group is for sure valuable 
for my future life. 
 
My beginnings here in Norway would be much more difficult, if there was nobody giving me 
advices with everyday “how-to” and “where is” problems. Therefore my big 
acknowledgments belong to my closest colleagues Dr. Pedro Osvaldo Miranda Chinea, Dr. 
Abhijit Datta Khoje, Steffi Munack and finally, Dr. Geir Kildahl-Andersen, for being there 
always ready with the advice when necessary. Special thanks belong to Matthias Maercz for 
helping me with microwave syntheses.   
 
Additional acknowledgments belong to Steffi Munack, Dr. Geir Kildahl-Andersen for 
comments, suggestion and proofreading during the writing process. Fredrik Lundvall is 
greatly acknowledged for helping me to conquer the “user-friendliness” of MS Word and for 
the last “facelift” comments on the thesis. The completion of this work would not be possible, 
without the help of Chris Ian Thomas whose skills of native English speaker were priceless 
for me. I mean invaluable, or inestimable? 
 
iii 
 
I would like to thank to Osamu Sekiguchi and Dirk Petersen for providing the analytical 
service and for discussions. I am very glad, that when I did not manage to solve the NMR 
problem myself there was always a chance “to give it to Dirk.” Thank You.  
 
Dear Matt, we had quite some nice time sharing our office. Having you around, both my 
chemistry knowledge as well as my English vocabulary was greatly enriched. Other big 
thanks belong to Kim Alex Fredriksen and the rest of our kjemi-innebandy team, for 
introducing me to the world of this exhausting sport. Many thanks to all present and former 
group members, colleagues and friends I met here in Norway.  
 
Very special thanks belong to one of my best companions from the Chemistry department - 
Bruker DPX200. Dear Two-hundred, sometimes (especially during the lonesome nights close 
to the unmercifully approaching deadline) you were my only friend who never let me down. 
Since you just reached your 20th birthday, I wish that students will treat you nicely so you can 
work properly for us for at least another 20 years. 
 
At this point I would like to dedicate a couple of words to my closest friends I met here over 
the years. 
 
Kydz,  
It is quite challenging to explain how grateful I am for everything you`ve done for me and for 
what we managed to do together. Let me give at least some examples such as all the birthday 
celebrations, the annual “Kalkuchaos” and “Put it to da faya” events. By the way, I hope that 
all the phrases I told you in Czech will be helpful for you. 
 
Prof. Chandra, thank you for teaching me little bit about the world around and a lot about the 
world of chemistry.  
 
Seppi, my deer, I believe you fulfil the true meaning of the word “schpumpanaden.” Thanks 
for your kindness, care and hospitality. The foody was always delicious. As I said some years 
ago: “No Seppi, no summer.” 
 
V for Fredrik, you with M.C. Post-Dog and Mr.G put always the highest standard, when it 
came to the general knowledge. Most importantly, I wish you to know that you are the only 
iv 
 
person I met that possess a samurai sword as well as the driving license for a snow-scooter. 
“Get to the choppah!” 
 
Mr. SuperGreen, I know that both of us we are operating on the same wave length. Yours all 
the time positive attitude always cheered me up. I wish all the best with Sasha and I am 
looking forward to buy the first LEGO for Alexander “da shorty.”  
 
Uncle Tapio, I will do this in Finnish way. Simply - Thank you. However, I would like to 
remind you, that you still owe me the lessons of ice-hockey. “Kultaa Suomelle!” 
 
M.C. Post-Dog, your rational sinking and down-to-earth attitude made you a real chieftain of 
“Peach Pit” and our tribe. I enjoyed our company a lot. However, I still think it was 
Vinderen… 
 
Mr. G, thanks to you I had the opportunity to taste the frozen Norwegian humour. In addition, 
introducing for example the song “Les Sucettes” to me is yet another unforgettable 
experience. 
 
Fiona, you made the best “Ken Lee, hi guys-curry” I`ve tasted. Good luck in your future 
career. 
 
I would like to thank to my parents and my family members for their love, support and 
patience. 
 
Finally, I want to thank my future wife Petra Krylová. There is so much I want to thank You 
for. However, there are no proper words yet invented to express it properly. I am constanly 
learning something new from you and you made me a better person in every way. I will never 
forget what you did for me over the past years and I am looking foreward to our future 
together. 
 
Jindřich Kania 
Oslo, February 2013  
 
 
v 
 
Summary 
The present thesis is focused on the design of synthetic routes towards asmarine 
analogues. Asmarines are marine natural products isolated from the sponges Raspalia sp. The 
asmarine molecule contains a seven-membered ring fused with a purine core. This 
tetrahydrodiazepinopurine moiety has previously been constructed for example by ring-
closing metathesis (RCM). We were focused on developing this RCM reaction pathway 
further, in order to introduce a chiral centre to the 7-membered ring.  
 
The attempts to employ chiral allylic amines in the strategy were not successful. 
However, we managed to achieve the synthesis of the seven-membered ring by a novel 
synthetic approach employing Ru-catalysed double bond migration and Cu-catalysed C-N 
coupling. Thus, a new method for double bond migration of N-allyl purines was successfully 
developed, involving the substrate 7-allyl-6-iodo-7H-purine and the catalyst 
RuClH(CO)(PPh3)3. Furthermore, the possibilities of C-N bond formation between tert-butyl 
allylcarbamate and 7-alkylated 6-halopurines were investigated. Suitable conditions for the 
coupling were determined using the Goldberg reaction and 6-iodo-7-(prop-1-en-1-yl)-7H-
purine was successfully coupled with tert-butyl allylcarbamate, giving tert-butyl allyl(7-
(prop-1-en-1-yl)-7H-purin-6-yl)carbamate. Finally, the RCM with this intermediate led to the 
previously known 7,8,9,10-tetrahydro-[1,4]diazepino[1,2,3-gh]purine. 
 
 
In addition, attention is paid to the synthesis and rearrangement of N-allyl to N-
propenyl purines. There are very few convenient routes to N-alkenylpurines in general. 
Therefore, we have carried out a study on the isomerisation of 9-allyl- and 7-allylpurines. 
Various N-allyl purines were prepared, and base- or transition metal complex promoted 
isomerisations were explored. Subsequently, this study was extended for substrates bearing 
additional substitution on the allyl chain. Scope and limitation of the double bond migration 
methodologies and E/Z selectivity is discussed. 
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Chapter 1  
Synthesis of asmarine analogues 
1.1 Marine natural products and bioprospecting 
The origin of modern medicine and pharmacology is strongly connected with products 
from organisms in nature. It is well documented throughout human history, that almost all 
medications have their origin in natural products from terrestrial organisms such as higher 
plants being the most traditional source.1 Nowadays, the share of natural products reaches 
above one-third of overall drug production.2,3 For example the hypolipidemic agent 
atorvastatin (Figure 1.1), which is the analogue of the fungal metabolites,4 ranked in the 35 
best selling pharmaceutical products in 2000, 2001, and 2002.2 The chemistry of natural 
products contributes considerably for example in the field of cancer and hypertensive 
treatment.2  
 
Figure 1.1 Structure of Atorvastatin.4 
An important trend in the discovery of novel bioactive molecules is the implementation 
of screening for marine secondary metabolites.3,5 The marine habitat is a promising reservoir 
of interesting organisms. In this unique environment, plants, animals and other 
microorganisms can produce various metabolites, which are structurally different from those 
found in terrestrial species.3,6 Interestingly, invertebrates such as marine sponges7 are known 
to produce a wide range of compounds for chemical defence.3 Even though the oceans cover 
more than 60% of the Earths biosphere, the natural products coming from the seas were 
somewhat overlooked until recently.1 The overall interest in marine natural products started 
approximately 60 years ago with the isolation of spongothymidine and spongouridine (Figure 
Chapter 1 
 
 
2 
 
1.2). Both these sponge-derived nucleosides were obtained from the Cryptothetia crypta 
sponge8 and possess antiviral activity. This discovery brought the attention to the field of 
marine natural products bioprospecting.1,9 
 
Figure 1.2 Antiviral nucleotides from Cryptothetia crypta sponge. 
Up to date, the screening for marine natural products has offered more than 14,000 
novel and structurally unique compounds with interesting bioactivities.1,7 However, marine 
product based analogues reached the level of therapeutic agents to a very little extent.1 A 
general problem concerning natural products is the high cost of the time demanding screening 
process3 and more importantly, the unavailability of the substances in acceptable amount.1 A 
drug production based on the isolation from the marine biomass is not feasible due to the 
limited availability of the compounds of interest. Moreover, harvesting marine species on a 
large scale would have a negative impact on the marine ecosystem.1 Hence, bioprospecting 
has to be connected with modern synthetic organic chemistry. The development of methods 
for the synthesis of newly discovered bioactive targets will unlock the possibility to fully 
investigate the real potential of such substances, if enough material can be produced. 
Furthermore, preparation of various synthetic analogues of natural products would allow 
extensive study of structure activity relationship and thereby enhance pharmaceutical effect or 
address some toxicity issues.6  
1.2 Asmarines 
Asmarines represent a relatively new class of nitrogen-containing metabolites from 
marine sponges. Currently, eleven different asmarines are reported.10-13 The first known 
asmarines A, B and C were isolated from Raspailia sp. living in the Red Sea.10 Later on, the 
structures of asmarines D, E and F, supplied from the same source, were described.11 
Asmarines G and H were obtained from the Indian ocean species of Raspailia sp.12 The 
remaining compounds I, J and K were isolated from Raspailia sp. located in the Madagascar 
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area.13 The asmarine molecules consist of three important structure parts: Particularly the 
terpenoid moiety which is attached to a diazacycloheptane, and a purine core which is fused 
with this 7-membered ring in positions C-6 and N-7 (Figure 1.3). All known asmarines can be 
sorted into three categories based on their structural properties. For example the asmarines C-
F possess a carbonyl group at C-8 of the purine unit, while a cyclopropane ring in the 
terpenoid part is a significant structural feature in case of the asmarines I and J. 
 
 
 
Figure 1.3 Structure of known asmarines.10-13 
From the biosynthetical point of view, the purine moiety is most probably originating 
from the adenine molecule.11  Thus, asmarines could be considered as adenine derivates. On 
the other hand, the presence of the bicyclic diterpenoid moiety assigns asmarines also to the 
group of clerodanes.14 Little is known so far about the bioactivity of these metabolites, 
however, asmarines A and B possess an interesting selective cytotoxicity to tumor cells.10 
This makes this class of compounds a very attractive target for the development of new 
pharmaceuticals. Unfortunately, as with all other marine natural products in general, 
asmarines are only available in very limited amounts. For instance the isolation of the 
asmarines A and B started with 20 grams of crude collected sponge material. The final 
amount of the obtained pure metabolites from this material did not exceeded 90 mg.10 
Moreover, asmarines C, D and E, F respectively were isolated as inseparable pairs of 
compounds.11 Therefore, an efficient and scalable synthetic route to obtain high amounts of 
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these natural products or their synthetic analogues is highly desired to allow an enhanced 
study of the pharmacological potential of this class of substances.15,16 
 
1.2.1 Previous work in the field of asmarine analogues synthesis 
After the first reports regarding the general structure of asmarines and their cytotoxic 
properties, there has been a rise in interest in the preparation of these molecules.17 Regarding 
the synthesis of the heterocyclic part, the crucial step is the construction of the 10-
hydroxytetrahydro[1,4]diazepino[1,2,3-g,h]purine system (THDAP). There are several 
possibilities for the formation of the bonds a-e (Figure 1.4). 
 
 
Figure 1.4 THDAP ring and the bonds a-e in the general structure of the asmarine. 
This thesis will focus on the synthesis of asmarine analogues via the formation of bond 
d. We established our study on the basis of recent contribution to the field, wherein the ring-
closing metathesis (RCM) was employed as the key step (Scheme 1.1).18 A detailed 
discussion regarding this original RCM approach as well as our following investigations of 
this methodology is presented in Chapter 3 and Chapter 4. The other reported synthetic routes 
leading to model compounds bearing a 7-membered ring are described below in this chapter. 
 
Scheme 1.1 The RCM reaction in the synthesis of the asmarine analogues. 
Before the asmarine structure was discovered, there was already a known procedure 
leading to the tricyclic fused ring system on the adenine molecule (Scheme 1.2). While 
ethanol and propanol derivates 4a and 4b reacted preferably with the N-1 position, the 
cyclisation reaction of the precursor N-(4-chlorobutyl)-N-methyl-9H-purin-6-amine (4c) 
occurred in the position N-7 and gave the product 5c with an 8-membered ring.19 
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Scheme 1.2 Reagents and conditions: (a) SOCl2, r.t., 3 h; (b) NaH, DMF, r.t., 2 h.19 
More importantly, the first successful formation of the THDAP ring was achieved during an 
investigation of the Michael addition with adenine derivates (Scheme 1.3).20 The reaction of 
adenine either with acrylic anhydride or vinyl acrylate resulted in the formation of the bonds b 
and e in one step. However, this procedure offered only limited yields of the cyclised product 
7.  
 
Scheme 1.3 Reagents and conditions: (a) acrylic anhydride, DMSO, 60 ºC, 24 h; vinyl acrylate, DMSO, 60 ºC, 
24 h.20 
The first synthesis directed towards the heterocyclic portion of asmarine molecule was carried 
out in 2001.17 In agreement with a previous report,19 the attempt to form the bond e with the 
propanol precursor 8 resulted in formation of an unwanted species 9 with a 6-membered ring 
(Scheme 1.4). 
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Scheme 1.4 Reagents and conditions: (a) SOCl2/CHCl3, r.t., 4 h.17 
Therefore, the N-7 alkylated intermediate 10 was chosen as a suitable starting point. The aim 
to construct bond b in the last step of the sequence successfully gave the desired THDAP 
system (Scheme 1.5).17 
 
Scheme 1.5 Reagents and conditions: (a) SOCl2, r.t., 1 h; (b) K2CO3, DMSO, 60 ºC, 3 days.17 
Subsequently, this approach was further developed. An important feature of this strategy is 
the presence of a protecting group in the N-9 position. The N-9 protection allows the 
preparation of a suitable N-7 alkylated precursor 14 with an appropriate functional group, 
which could then be available for the following cyclisation (Scheme 1.6). Among the several 
groups tested, the cyanoethyl group or diphenyl methyl group were found to be the most 
suitable.21,22 
 
Scheme 1.6 General pathway for the formation of the bond b developed by Pappo et al.17,21,22 
The synthesis of the THDAP system was thereafter also achieved using 4 different cyclisation 
methods such as the Mitsunobu alkylation (Scheme 1.7),21,22 the iodocyclisation or 
aminomercuration (Scheme 1.8),22 and the acid catalysed cyclisation (Scheme 1.9).22  
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Scheme 1.7 Reagents and conditions: (a) TFA, CH2Cl2, r.t., 24 h; (b) DIAD, PPh3, THF, r.t. to 40 ºC, 24 h; (c) 
30% HBr/AcOH, 100 ºC, 3.5 h.21 
 
Scheme 1.8 Reagents and conditions: (a) K2CO3, MeOH, r.t., 1 h; (b) I2, NaHCO3, EtOH, r.t., 48 h; (c) Bu3SnH, 
THF, Δ, 3 h; (d) 1) Hg(OAc)2, THF, 40 ºC, 24 h, 2) NaBH4/NaOH; (e) 30% HBr/AcOH, 100 °C, 3 h or DDQ, 
CH2Cl2/H2O, r.t., 4 h.22 
 
Scheme 1.9 Reagents and conditions: (a) 15% HBr/AcOH, r.t., 12 h; (b) 30% HBr/AcOH, 100 °C, 3 h.22 
Several novel asmarine analogues were successfully prepared in this fashion. In addition, 
another derivate was prepared again by the parallel construction of the bonds b and e (Scheme 
1.10). The 3-trimethoxyphenylmethyl group directed the N-alkylation with 1,3-
dibromopropane to the N-7 position, which then resulted in the formation of 7-membered ring 
system. The cyclised product was deprotected and isolated in high yield.21  
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Scheme 1.10 Reagents and conditions: (a) Et3N, DMA, 80 ºC, 36 h; (b) 30% HBr/AcOH, 100 ºC, 1 h.21 
So far, no examples regarding the construction of the bond c are reported in the 
literature.16 In another preliminary study towards the total synthesis of asmarines, the 
formation of the bond a via intramolecular C-6 amination was explored (Scheme 1.11). The 
cyclisation precursor 31 was prepared from the pyrimidine derivate 30 by N-alkylation 
followed by a cyclocondensation. The alloc group was removed from the cyclisation 
precursor 31 in the presence of 2-ethylhexanoic acid and the catalyst Pd(PPh3)4. The resulting 
hydroxylamine intermediate was cyclised under basic conditions. The target product was 
isolated after deprotection with a good yield. 
 
Scheme 1.11 Reagents and conditions: (a) 1) Pd(PPh3)4, PPh3, 2-ethylhexanoic acid, CH2Cl2/Et2O, 2) Et3N, n-
BuOH; (b) HCl, THF, 55 ºC, 1.5 h.23 
The deprotection and intramolecular C-6 amination was further employed in the synthesis of 
analogues 36 with C-8 carbonyl group, related to the asmarines C, D, E and F.  Two derivates 
were prepared from the suitable N-7 alkylated 8-oxopurine in this fashion (Scheme 1.12).  
 
Scheme 1.12 Reagents and conditions: (a) alkylbromide, K2CO3, n-Bu4NI, DMF, r.t., 22 h; (b) 1) TFA, CH2Cl2, 
2) Et3N, n-BuOH, Δ, 2 h.23 
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In addition to the reported synthesis of the asmarine heterocyclic core, the construction of the 
decaline moiety of asmarine A and B was also developed.14  
 
 
Scheme 1.13 (a) 1) ClMgCH2SiMe2Ph, Et2O, 0 ºC, 2) o-iodoxybenzoic acid, EtOAc, 76 ºC; (b) (R)-Me-CBS-
oxaza-borolidine, BH3, THF, -50 ºC; (c) 1) Hg(OAc)2, EtOCH=CH2, 35 ºC 2) SiO2; (d) cyclohexenone, PEt3, 
catalyst 42; THF, -10 ºC; (e) BF3.OEt2, CH2Cl2, -78 ºC to -10 ºC.14 
1.2.2 The current project 
This work is a part of a larger on-going project towards the asmarines. Up to this date, 
no total synthesis of the natural asmarines A-K was achieved.16 The reports related to 
synthesis of asmarine analogues show so far, that only racemic analogues can be prepared.15,16 
The chiral centre with (S)-configuration is a common feature for all the THDAP systems in 
naturally occurring asmarines, and the construction of this centre still remains a challenge. 
Moreover, any methods based on the construction of the bond b or c seems to be less feasible 
since the cyclisation step would have to be enantioselective. From this point of view, an 
introduction of the allylic amine intermediate possessing the (S)-chiral centre in the α-position 
seems a promising approach (Scheme 1.14). Subsequently, the target natural product could be 
obtained by the RCM reaction from this precursor molecule. The RCM might be a very 
elegant method, since it will not disrupt the stereochemistry during formation of the final 
THDAP ring. 
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Scheme 1.14 Retrosynthetic analysis of the possible total synthesis of asmarine. 
Therefore, the primary objective of this project was to introduce a chiral centre on the 
tetrahydrodiazepinopurine moiety using chiral allyl amines (Scheme 1.15).  
 
Scheme 1.15 Chiral allyl amines in the strategy towards asmarine analogues. 
The success of this reaction pathway would open the possibility of a total asmarine synthesis. 
In addition, the synthetic routes towards the decaline intermediate 43 applicable for this 
protocol are currently carried out in the Gundersen group at the University of Oslo.  
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Chapter 2  
Synthesis of N-allyl purines 
2.1 Introduction 
Several N-7 allyl substituted purines were synthesized as precursors for the asmarine 
directed synthesis (Chapters 3 and 4). Furthermore, N-9 or N-7 allylic derivates with 
substitution on the allyl chain were prepared (Scheme 2.1) to be used as substrates for the 
study of double bond migration in these systems (Chapter 5).The first part of this chapter 
gives an overview of the various methods applicable for synthesis of N-allyl purines. Typical 
trends in purine N-alkylation are presented herein, as well as the possibilities of regioselective 
synthesis. 
 
Scheme 2.1 Preparation of various N-allyl purines. 
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2.1.1 Synthesis of N-allyl purine by N-alkylation 
Poor regioselectivity in the N-alkylation of purines is a common issue mentioned in the purine 
chemistry literature.24-27 The site of N-alkylation is dependent on the alkylating reagent and 
the reaction conditions.  Also, the presence and position of other substituents in the molecule 
is important.24,25,28,29  
6-Halo-purines, when treated with alkylating agents, give rise to isomeric mixtures of N-7 and 
N-9 alkyl purines with the N-9 alkyl purine usually obtained in excess.24,25,30  This 
phenomenon is caused by the π-electron rich imidazole ring24 as well as by the 
electronegative 6-halo substituent. Halogen has a deactivating effect on the pyrimidine 
moiety, leaving N-7 and N-9 as the only reactive positions.31 Dominant formation of the N-9 
product is due to steric shielding of the N-7 position by the C-6 substituent.29 Typical 
procedures for the synthesis of N-allyl-6-halo-purines (Scheme 2.2) are summarized in Table 
2.1. First of all, N-allyl-6-halopurines can be obtained in good yields from alkylation with 
allylhalides under basic conditions (Table 2.1, entries 1-4, 8 and 9).32-36 Another option is 
palladium catalysed alkylation using allyl acetate (Table 2.1, entries 5 and 7).37,38 In addition, 
Mitsunobu type of allylation with allyl alcohol was also recently reported (Table 2.1, entry 
6).39 
 
 
Scheme 2.2 Allylation of different 6-halopurines. 
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Table 2.1 Conditions for allylation of 6-halopurines 
Entry Subst. R2 R6 
Alkyl 
agent 
Conditions 
N-9 (48) 
[%]a 
N-7 (49) 
[%]a 
132 6b H Cl  KOH/Aliquat, r.t. 58 23 
233 6b H Cl  NaH/DMF, r.t. 65 n.d.
b 
334 6b H Cl  K2CO3/DMF, r.t. 67 n.d. 
435 6b H Cl  NaH/DMF, r.t. 60 n.d.
c 
537 6b H Cl  Pd(PPh3)4, THF/DMF, 50 ºC 48 32 
639 6b H Cl  DEAD, PPh3, THF, 70 ºC 78 n.d. 
738 6c NH2 Cl  Pd(PPh3)4, Cs2CO3/DMSO, 45 ºC 18 20 
835 6c NH2 Cl  NaH/MeCN, r.t. 56 n.d. 
936 6d H I  K2CO3/MeCN, Δ 77 n.d. 
aIsolated yields; bNot determined; cFormed, not isolated. 
 
In the case of 9H-purin-6-amine (6a), the N-alkylation pattern is a complex area. In 
general it is stated24-26 that adenines give mainly N-3 products, when alkylated under neutral 
conditions.40-43 Some of the N-9 and N-1 alkyl isomers may also be present.24 Adenines 
cannot be alkylated in acidic media.24,25 Regarding the alkylation under basic conditions, N-
7/N-9 regioselective substitution was initially reported.44-46 The phenomenon of the N-7 
product formation was later on reinvestigated and found to be a misconception.47 This 
misconception was mainly caused in its time by the absence of  modern techniques for proper 
structure elucidation, as well as by the fact, that N-3 and N-7 isomers show great similarity in 
physical properties.24,47 It is now generally accepted, that adenine alkylation under basic 
conditions gives mainly N-9 and N-3 alkyl isomers.24,25 Thus, when adenine is treated with 
allyl halide in basic solution, a mixture of several different regioisomers is usually obtained, 
where the 9-alkyl-adenine is the major one followed by the N-3 isomer.32,48 The N-7 isomer 
could be present in the mixture in trace amounts. Several examples of the allylation and the N-
3 product formation under basic conditions can be found in the literature (Table 2.2).  
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Table 2.2 Allylation of adenines under basic conditions 
Entry Subst. Solv. Alkyl agent base N-9 
[%]a 
N-3 
[%]a 
148 Adenine 6a H2O Triallylphosphate NaOH 31 35 
232 Adenine 6a Neat  KOH 46 27 
349 
8-Br-6-(piperidin-1-yl)-
9H-purine 
DMF  K2CO3 35 58 
450 Adenine 6a Ethanol  Na n.d.
b 46 
551 Adenine 6a DMF  K2CO3 27 n.d. 
aIsolated yields; bMinor amounts of N-9 product formed, removed by crystallisation. 
 
2.1.1.1 Regioselective N-7 alkylation 
As mentioned above, the N-alkylation yields the N-7 products only in limited amounts 
and is not applicable for adenines. Nevertheless, it is possible to access the N-7 alkylated 
purines from the N-alkylation with a good yield, when transient protection by 
methylaquacobaloxime (50) is employed. The principle of this method is based on a 
reversible coordination of the cobaloxime complex 50 to the different nitrogen atoms in the 
purine ring. The C-6 substituent is blocking the complex from coordinating to the N-7 
nitrogen. Instead, water from the methylaquacobaloxime is first replaced by the N-3 nitrogen 
of the purine. The complex is further stabilized by an intramolecular hydrogen bond between 
the hydrogen atom in the N-9 position and the oxygen from the cobaloxime. After 
coordination to N-3, the bulk of the cobalt complex is actually blocking the N-9 nitrogen, 
leaving the N-7 readily available for the N-alkylation step.52 The resulting complex of 
cobaloxime with the 6-chloro-9H-purine (6b) was successfully isolated and characterized by 
X-ray crystallography (Figure 2.1).52 The most important advantage of this method is that 
reasonable yields of 7-substituted products are obtained in a single step. The literature reports 
show so far, that this procedure was successfully utilised with the reactive organohalides such 
as allyliodide or 2-bromoacetophenone and 6-halopurines52-55 or 6-(furan-2-yl)-9H-purine.56  
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Figure 2.1 Structure of the 1:1 complex of mehylcobaloxime 50 with 6-chloro-9H-purine 6b.52 
Recently, a new and efficient broad-scope method for the preparation of 7-substituted 
6-halopurines has been developed.57,58 This protocol is based on a sequence of 4 steps starting 
with the Boc-protection of the N-9 nitrogen. The key step of this sequence is the reduction of 
the imidazole moiety from the N-9 protected purine. The reduction converts the N-7 position 
into a secondary amine and allows facile alkylation on this site. The resulting products were 
re-aromatised and obtained in good overall yield (Scheme 2.3). 
 
 
Scheme 2.3 7-Substituted purines prepared via 7,8-dihydropurines.57,58 
2.1.2 Introduction of the amino group 
 Halogen atoms in purines can be easily replaced with ammonia and primary or 
secondary amines.24,25 For example 6-chloropurine can in this manner be simply converted to 
adenine.59 To achieve the amination with ammonia, forcing (e.g. sealed tube) conditions are 
usually required. The amination reaction is typically performed in refluxing alcoholic 
solution.24 Literature procedures for the amination, which were applied in the experimental 
part, are given in Scheme 2.4.53,60 
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Scheme 2.4 Reagents and conditions: (a) NH3/MeOH, 50 ºC, 15 h;60 (b) NH3/t-BuOH, 100 ºC, 21 h.53 
A two step procedure with p-methoxybenzylamine could be an alternative method for 
the introduction of the free amino group.61 In the first step of the sequence, the chloropurine 
55a is treated with p-methoxybenzylamine. The nucleophilic substitution gave the N6-
benzyladenine 56, which was subjected to debenzylation conditions with TFA. The adenine 
derivate 55b was isolated with good overall yield (Scheme 2.5). This approach is useful for 
substrates, which require a stronger nucleophile than the ammonia for the SNAr (Nucleophilic 
Aromatic Substitution) to take place.61 
 
Scheme 2.5 Reagents and conditions: (a) p-methoxybenzylamine, n-BuOH, Δ, 24 h; (b) TFA, 60 ºC, 2 h.62 
2.1.3 Methoxylation 
The methoxylation is usually carried out in a similar fashion to the amination (Section 
2.1.2). The methoxy purines are prepared from the corresponding halo analogues via halogen 
replacement. The most typical conditions employ sodium methoxide in alcoholic solution at 
ambient temperature or heating (Scheme 2.6).24,63,64 
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Scheme 2.6 Reagents and conditions: (a) MeONa, MeOH, Δ, 2 h. 
In addition to the standard methoxylation conditions, mild conditions for the 
introduction of various alkoxy groups were reported (Scheme 2.7).65 In this particular case, 
the nitro group from substrate 58a was replaced by the alkoxy group from the corresponding 
alcohol by refluxing in the presence of potassium fluoride.  
 
Scheme 2.7 Reagents and conditions: (a) ROH, KF, 50-100 ºC.65 
 
2.2 Results and discussion 
2.2.1 Allylation under basic conditions 
Several N-9 and N-7 allyl purines were prepared using allyl bromide and potassium 
carbonate (Scheme 2.8, Table 2.3).34,66 As expected, with the 6-chloropurine as starting 
material, the allylation yielded the major N-9 isomer 48b in high excess compared to the N-7 
allyl purine 49b. When 6-iodo-9H-purine (6d) was alkylated, a decrease in formation of the 
N-7 isomer 49d was observed (Table 2.3, entry 3) as expected based on previous reports.36,67  
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Scheme 2.8 Reagents and conditions: (a) allyl bromide, K2CO3, DMF, r.t., 17 h. 
 
Table 2.3 Alkylation of the 6-halogen purines 
 Comp. Ratio of productsa  Yield [%]b 
Entry No. R6 R2 
N-9 
(48) 
N-7 
(49) 
N-9 
(48) 
N-7 
(49) 
1 6b Cl H 71 29 64 22 
2 6c Cl NH2 80 20 78 14 
3 6d I H 83 17 69 10 
aRatio determined by 1H NMR of the crude product; bIsolated yield. 
 
Apart from the N-allyl halopurines 48b-d and 49b-d, preparation of the 9-allyl-9H-
purin-6-amine (48a) and its N-7 analogue 49a was required for the double bond migration 
study (Chapter 5). One of the earlier reports51 on adenine allylation mentions only single N-9 
product 48a, but with poor yield. This indicates possible formation of other by-products, 
which were probably removed during purification and not isolated. In other case it was 
reported, that when adenine 6a was treated with allyl bromide and NaH in DMF, a mixture of 
48a and 49a was obtained. N-7 isomer 49a was removed during flash chromatography.35 We 
attempted to reproduce this procedure, in order to investigate whether both the desired 
products 48a and 49a can be obtained from this reaction. We acquired 9-allyl-9H-purin-6-
amine (48a) and 3-allyl-3H-purin-6-amine (59) instead. The desired N-7 isomer (7%) as well 
as other multiple alkylated products was detected by 1H NMR, but not successfully isolated 
(Scheme 2.9). Comparable results were achieved when the milder base Cs2CO368 was used. 
Since the direct allylation of adenine 6a did not afford the desired N-7 product 49a, another 
approach starting from the compound 6b was chosen (Sections 2.2.4).  
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Scheme 2.9 Reagents and conditions: (a) NaH, allyl bromide, DMF, r.t., 24 h. 
2.2.2 Regioselective N-7 alkylation 
In the synthesis towards asmarines we were interested in simple methods for the 
preparation of N-7 allyl purines. Among the methods described in section 2.1.1.1, the method 
proceeding via methylaquacobaloxime (50) was chosen.  The methylaquacobaloxime 
complex 50 can be easily prepared from commercially available CoCl2 and dimethylglyoxime 
(Scheme 2.10).69 
 
 
Scheme 2.10 Preparation of the methylaquacobaloxime 50. 
The alkylation of 6-chloro-9H-purine (6b) as well as 2,6-dichloro-9H-purine at N-7 by 
allyl bromide using protection with methylaquacobaloxime has been previously shown.52 In 
our case, when allyl bromide was used, we managed to isolate the final product 49b in 40% 
yield. The yield of 49b was improved to 69% when the allyliodide was used instead (Scheme 
2.11). 
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Scheme 2.11 Reagents and conditions: (a) methylaquacobaloxime, allyl bromide, MeCN, r.t. 4 days; (b) 
methylaquacobaloxime, allyliodide, MeCN, r.t. 4 days. 
 Compounds 49c and 49d were isolated as minor products from the standard alkylation 
reaction before (Table 2.3, entries 2 and 3). In order to obtain higher amounts of these N-7 
alkylated materials, the procedure using methylaquacobaloxime was also applied for the 
purines 6c and 6d (Scheme 2.12), extending the scope of this N-7 regiospecific alkylation. 
The starting material 6c was fully consumed after 72 h and the undesired N-9 product 48c was 
not detected using TLC during reaction progress. The product 49c was purified by repeated 
column chromatography on silica and further recrystalized from EtOAc.  This gave 
cobaloxime residue free material, as judged by 1H NMR. The final yield of the compound 49c 
was increased compared to the standard alkylation conditions, but still deserves further 
improvement (Table 2.4, entry 2). While attempting to employ 6-iodo-9H-purine 6d in this 
reaction protocol, we proved that after the cobaloxime is coordinated, a relatively large iodine 
group in the C-6 position does not prevent successful alkylation. The product 7-allyl-6-iodo-
7H-purine (49d) was isolated in good yield (Table 2.4, entry 3). 
 
 
Scheme 2.12 Regents and conditions: allyliodide, K2CO3, MeCN, r.t. 
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Table 2.4 Regioselective allylation with cobaloxime 
Entry No. R6 R2 Time [h] 
Yield 
[%]a (49) 
1 6b Cl H 96 69 
2 6c Cl NH2 72 32 
3 6d I H 120 61 
aIsolated yield. 
2.2.3 Alkylation with substituted allyl and homoallyl halides  
The type of the alkyl halide chain has an impact on the regioselectivity of the 
alkylation (Scheme 2.13, Table 2.5).  When allyl bromide was used in the alkylation of purine 
6b, the resulting ratio of the products was in the range of 70:30 for N-9 product 48b and N-7 
isomer 49b, respectively (Table 2.3, entry 1). A similar behaviour was observed in the 
alkylation by C-3 substituted allyl halides (Table 2.5, entries 1-3). A minor change in 
regioselectivity was observed, when 3-bromo-2-methylprop-1-ene was applied in the reaction. 
The conversion towards N-9 increased to 75%, leading to the N-9 regioisomer 62a in 68% 
isolated yield (Table 2.5, entry 4). Purines 64 and 65 bearing the homoallylic side chain were 
observed as minor by-products from the rearrangement reactions (see Section 5.2.4, page 100, 
Scheme 5.25). These terminal alkenes were not isolated in pure form. Hence, the structure 
confirmation was based on comparison with 1H NMR spectra of reference compounds, which 
were synthesized by N-alkylation of purines with corresponding homoallylic halides. These 
reactions showed slightly higher selectivity towards N-9 alkylated products (Table 2.5, entries 
5 and 6). 
 
 
Scheme 2.13 Reagents and conditions: (a) alkyl halide (Table 2.5), K2CO3, DMF, r.t. 17 h. 
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Table 2.5 Alkylation with allyl and homoallyl halides 
 Comp. Ratio of productsa Yield [%]b 
Entry R-Br N-9  N-7  N-9  N-7  
1  70 30 62, 60a 29, 61a 
2  70 30 63, 60b 27, 61b 
3  71 29 68, 60c 27, 61c 
4  75 25 68, 62a 23, 63a 
5  80 20 74, 64a 16, 65a 
6  83 17 73, 64b 9, 65b 
aRatio determined by 1H NMR of the crude product; bIsolated yield. 
 
2.2.4 Amination of 6-chloropurines 
For the preparation of 7-allyl-7H-purin-6-amine (49a), halogen replacement 
procedures were performed. Initial attempts to introduce the amino group to the C-6 position 
were carried out by stirring compound 49b in heated solution of sat. NH3 in MeOH.60  
Unfortunately, following this procedure offered only a limited overall conversion, very small 
amount of the desired compound 49a and a methoxy analogue 49e as the major product 
(Scheme 2.14).  
 
 
Scheme 2.14 Reagents and conditions: (a) sat. NH3/MeOH, sealed tube, 50 ºC, 15 h. 
After this initial lack of success, the product 49a was successfully generated in another 
fashion (Scheme 2.15). The amino group was introduced by a two step procedure, starting 
with a nucleophilic substitution of 49b with p-methoxybenzylamine. The p-methoxybenzyl 
group from the intermediate 66 was then cleaved off under acidic conditions70 affording the 
desired 7-allyl-7H-purin-6-amine (49a) with a good yield. Another option was to treat the 
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starting material 49b with a saturated NH3/t-BuOH solution.53 The solvent t-BuOH was 
selected to prevent the formation of the unwanted alkoxy products. This particular approach is 
very convenient, affording full conversion and good yields in a single step (Scheme 2.15). 
Therefore, this method was chosen as a general method for the synthesis of N-allyl adenine 
analogues (Scheme 2.16, Table 2.6). 
 
 
Scheme 2.15 Reagents and conditions: (a) p-methoxybenzyl amine, DIPEA, n-BuOH, '2 h; (b) TFA, 70 qC, 48 
h; (c) sat. NH3/t-BuOH, sealed tube, 120 qC, 21 h.53 
 
 
Scheme 2.16 Reagents and conditions: (a) sat. NH3/t-BuOH, sealed tube, 120 qC, 21 h.53 
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Table 2.6 Amination of 6-chloropurines 
 Comp. Yield [%]a Comp. Yield [%]a 
Entry R s.m. N-9 Entry R s.m. N-7 
1  60a 95, 60d 7  61a 97, 61d 
2  60b 91, 60e 8  61b 77, 61e 
3  60c 86, 60f 9  61c 80, 61f 
4  62a 91, 62b 10  63a 87, 63b 
5  64a 95, 64c 11  65a 95, 65c 
6  64b 96, 64d 12  65b 44, 65d 
aIsolated yield. 
 
2.2.5 Synthesis of N-allyl-6-methoxy-purines 
 To broaden the scope of the double bond rearrangement study on N-allyl purines 
(Chapter 5), substrates bearing a methoxy group in C-6 position were prepared from the 
corresponding 6-chloro analogues. Two procedures for the C-6 methoxylation were evaluated 
(Scheme 2.17). 
 
Scheme 2.17 (a) sat. KF/MeOH, ∆, 4 days, 87%; (b) MeONa/MeOH, r.t., 48 h. 
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First, compound 48b was stirred with KF in MeOH.65 The reaction showed 
unfortunately no detectable progress after 24 h. Minor formation of the desired methoxy 
product 48e was observed already after the first 2 hours of the reaction, when the starting 
material 48b was refluxed in saturated KF/MeOH solution (Scheme 2.17). However, to reach 
completion, the reaction required a rather extensive time of 4 days. The best result was 
obtained when the combination of MeONa in MeOH was used. Most of the material 48b was 
consumed within the first 24 h of the reaction at room temperature and full conversion 
required 48 hours. The desired product 48e was isolated in good yield and this method was 
therefore applied for the synthesis of 49e as well. 
2.3 Summary and conclusions 
Various N-alkyl-6-halopurines were prepared using N-alkylation under basic 
conditions. The N-9 alkylated products 48, 60, 62 and 64 were isolated as major products.  N-
7 alkylated products 49, 61, 63 and 65 were obtained in lower amounts. N-allylation of 
adenine 6a yielded excess of the 9-allyl-9H-purin-6-amine (48a) and N-3 regioisomer 3-allyl-
3H-purin-6-amine (59). Regarding the N-7 regiospecific cobaloxime promoted allylation, the 
scope of this reaction was extended for the substrates 6-chloro-9H-purin-2-amine (6c) and 6-
iodo-9H-purine (6d). The N-7 products 7-allyl-6-chloro-7H-purin-2-amine (49c) and 7-allyl-
6-iodo-7H-purine (49d) prepared by regiospecific allylation were obtained in better yields 
compared to the standard basic allylation. 7-Allyl-7H-purin-6-amine (49a) was not available 
by allylation, but prepared via amination of the 7-allyl-6-chloro-7H-purine (49b). N-Alkyl 
adenines 60-65 were obtained in high yields using the same amination method. The 9-allyl-6-
methoxy-9H-purine (48e) and 7-allyl-6-methoxy-7H-purine (49e) were successfully prepared 
in high yields from the appropriate 6-chloropurines 48b and 49b respectively, employing 
MeONa in MeOH.  
2.4 Experimental 
7-Allyl-7H-adenine (49a) 
7-Allyl-N-(4-methoxybenzyl)-7H-purin-6-amine 66 (0.910 mmol, 270 mg) was heated in 1 ml 
of trifuloroacetic acid at 70 ºC for 48 h. The mixture was cooled down and the acid was 
removed in vacuo. The remaining thick sludge of the product was adsorbed on silica and 
purified by flash chromatography using MeOH:DCM (1:9); yield 135 mg (84%), colourless 
powder. Data are available in appendix I, compound 3a.  
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7-Allyl-6-chloro-7H-purin-2-amine (49c)  
6-Chloro-9H-purin-2-amine (2.38 mmol, 0.404 g) (6c) was stirred in dry MeCN (24 mL) 
under N2. Methylaquacobaloxime 50 (2.62 mmol, 0.844 g) was added in small portions. After 
5 min. K2CO3 (2.62 mmol, 0.362 g) was added. The mixture was stirred for another 30 min. 
Allyliodide (4.76 mmol, 0.435 mL) was injected through septum and the mixture was stirred 
in the dark for a total of 72 h. The solvent was removed in vacuo and the residue transferred 
to a separatory funnel using CH2Cl2 (100 mL) and aq. NaOH (2 M, 100 mL). The phases were 
separated and the aqueous phase was extracted with CH2Cl2 (3 x 50 mL). The combined 
organic layers were washed with brine (1 x 30 mL), dried with MgSO4, filtered and 
evaporated in vacuo. Product was purified two times by flash chromatography on silica gel 
using acetone/CH2Cl2 (4:6) as eluent. The chromatography was followed by recrystallization 
from EtOAc in order to obtain the cobaloxime free product; yield 158 mg (32%), yellow 
crystals. Spectral data were in a good agreement with those reported before.38 
7-Allyl-N-(4-methoxybenzyl)-7H-purin-6-amine (66)  
7-allyl-6-chloro-7H-purine 49b (1.54 mmol, 300 mg) and DIPEA (3.08 mmol, 0.540 mL) 
were stirred in n-BuOH (8.30 mL) at ambient temperature under N2 for 5 min. After addition 
of p-methoxybenzylamine (7.7 mmol, 1.0 mL) the reaction mixture was refluxed for 2 h. The 
mixture was evaporated in vacuo. The product was purified by flash chromatography using 
MeOH/CH2Cl2 (1:19); yield 425 mg (93%), off-white powder, mp 156-158 °C. 1H NMR 
(CDCl3, 400 MHz) G3.76 (s, 3H, OC+4.63 (d, J = 5.1 Hz, 2H, CH2'), 4.84 (m, 2H, NCH2), 
4.98 (d, J = 17.2 Hz, 1H, HA in =CH2), 5.24 (d, J = 10.4 Hz, 1H, HB in =CH2), 5.38 (t, J = 5.1 
Hz, 1H, NH), 5.98-6.07 (m, 1H, CH=), 6.82 (d, J = 8.8 Hz, 2H, =CH in Ph), 7.20 (d, J = 8.4 
Hz, 2H, =CH in Ph) 7.77 (s, 1H, H-8), 8.49 (s, 1H, H-2)13C NMR (CDCl3, 75 MHz) 44.6 
(CH2'), 49.5 (NCH2), 55.2 (OCH3), 111.9 (C-5), 114.0 (Ph), 119.3 (=CH2), 129.1 (Ph), 130.1 
(Ph), 133.4 (CH=), 144.5 (C-8), 150.3 (C-6), 153.3 (C-2), 159.0 (Ph), 159.9 (C-4); MS (EI) 
m/z (rel. int.) 295 (46, M+), 174 (18), 159 (12), 136 (23), 121 (100); HRMS (EI) C16H17N5O 
requires 295.1433, found 295.1433. 
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Chapter 3  
Synthesis towards asmarines starting from α-amino acids 
3.1 Introduction 
This chapter focuses on the attempted synthesis of asmarine analogues carrying 
substituents on the tetrahydrodiazepine ring. In principal, we wanted to explore, whether the 
7-membered ring with additional α-substituent can be formed via RCM reaction. Thus, three 
asmarine analogues 47 derived from α-aminoacids phenylalanine, valine and leucine were 
designed in order to develop methods, which could be applied in the total synthesis of natural 
asmarines (Figure 3.1). The position and configuration of the chiral centre of 47 is related to 
the natural occurring asmarines (Chapter 1, page 3, Figure 1.3).10,11,71 
 
Figure 3.1 Asmarine analogues derived from α-aminoacids. 
The initial part of this chapter describes the previously reported preparation of the 
asmarine analogue 7,8,9,10-tetrahydro-[1,4]diazepino[1,2,3-gh]purine 2 using RCM (Scheme 
3.1 and Scheme 3.4). This strategy was developed by Vik et al.18 from the Gundersen group. 
Following the idea of this report, we tried to utilize and to increase the scope of this synthetic 
pathway in the current study towards new asmarine analogues (see page also 10, Scheme 
1.15).  
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Scheme 3.1 RCM strategy towards asmarine analogues. 
3.1.1 Ring closing metathesis 
The RCM is a powerful synthetic method for the preparation of cyclic structures via 
carbon-carbon (C-C) bond formation. The new C-C bond is formed by exchange of the 
alkylidene groups on alkenes. The main advantage of this methodology72 is the relatively 
facile preparation of olefin substrates, which are usually more stable than the other precursors 
for C-C bond formation such as aldehydes, halides or triflates.73 The conventionally accepted 
metallacyclobutene mechanism is shown in scheme 3.2.72,74,75  
 
Scheme 3.2 Metallacyclobutene mechanism of the ring closing metathesis. 
During the past 15 years, the RCM reaction has become a common method in organic 
synthesis and a number of transition metal catalysts have been developed (Figure 3.2). 
Catalysts based on ruthenium are commonly used because of their air and moisture stability 
and tolerance to different functional groups. In addition, ruthenium catalysts 68a-c can be 
handled using standard organic techniques.75,76 For the synthesis of asmarine analogues, we 
chose the catalyst 68c, for its ability to close larger rings.77-79 Suitable alternatives are the 
Schrock (e.g. 69a, Figure 3.1)76 molybdenum-based catalysts,80 which have a broad scope of 
applications, but possess a much higher sensitivity to air and moisture.73,74 
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Figure 3.2 Structures of the typical RCM catalysts. 
RCM reactions are commonly used for the synthesis of heterocycles or aromatic 
compounds.76 Some difficulties were experienced in the cyclisation of amine containing 
systems.  The electron donating properties of the amino group may interfere with the 
metathesis, if coordination of the amine lone pair to the metal centre is possible.73,74,81 This 
complication can be efficiently overcome either by protonation of the amine,81 or by a 
protection strategy in order to convert the amine for instance to an amide, carbamate or 
sulfonamide.73,74  In some particular cases, the yield of the ring-closed product is strongly 
dependent on the type of the protecting group (Scheme 3.3).82,83  
 
Scheme 3.3 Example of the impact of the protecting group on RCM reaction.82 
RCM has a broad scope of application for example in the synthesis of natural products, 
medicinal chemistry or in the field of polymer and material chemistry. Due to the increasing 
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importance of the RCM in the organic synthesis, the discovery and development of this 
methodology was awarded with the Nobel Prize in Chemistry in 2005. 
3.1.2 Construction of the tetrahydrodiazepinopurine ring system by ring 
closing metathesis 
Herein, an overview regarding the synthesis of the asmarine analogue 2 is presented 
(Scheme 3.4).18 In the synthetic route to 2, there are several interesting synthetic aspects, 
which will be discussed further in the following chapters. The regiospecific N-7 alkylation 
(Section 2.2.2, page 19) plays a principal role in the reaction route. The target 2 could be 
considered as N-7 alkyl purine. Thus, the easily accessible 7-allyl-6-chloro-7H-purine (49b) 
was used as a suitable starting point. Replacing the halogen from 49b by allyl amine provided 
a product 72 with two allylic side chains. One of the challenges regarding the formation of the 
tetrahydrodiazepinopurine ring was the preparation of the N-7 propenyl intermediate 1.  
Fortunately, an elegant possibility to obtain alkenylpurine 1 was discovered, when compound 
72 was refluxed in MeCN in the presence of K2CO3. The selective double bond migration on 
N-7 allyl occurred, giving N-allyl-7-(prop-1-en-1-yl)-7H-purin-6-amine (1) as a pure Z-isomer 
in quantitative yield. This discovery opened a unique opportunity to approach the synthesis of 
the 7-membered ring. The ring closing, when attempted on the free secondary amine 1 was 
not successful. Consequently, the Boc group was introduced prior to the RCM. The secondary 
amine 1 showed notably low reactivity under the Boc-protection conditions, nevertheless, the 
compound 73 was obtained in good yield. The ring-closing of 73 gave the desired 
intermediate 74 in high yield. The successful RCM was followed by reduction and 
deprotection of 74 to afford the final asmarine analogue 7,8,9,10-tetrahydro-
[1,4]diazepino[1,2,3-gh]purine (2) (Scheme 3.4). Alternatively, application of the methyl in 
place of the Boc group was explored, but ring-closing did not occur. This indicated that the 
nature of the N-protecting group is important for the RCM reaction to take place. 
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Scheme 3.4 Reagents and conditions: (a) allylamine, pyridine, 100 ºC, 16 h;  (b) K2CO3, MeCN, Δ, 17 h; (c) 
(Boc)2O, DMAP, MeCN, r.t., 4 days; (d) Hoveyda-Grubbs II, DCE, ∆, 1.5 h; (e) 1) H2, Pd/C, EtOAc, 2) HCl/ 
MeOH, r.t., 1 h.18 
3.2 Results and discussion 
3.2.1 α-Amino acids in the synthesis towards asmarines 
In order to introduce the substitution to the diazepine ring, the chiral amines 45a-c 
derived from α-amino acids phenylalanine, valine and leucine had to be synthesized (Scheme 
3.5).  
 
Scheme 3.5 The role of the chiral amines 45a-c in the synthetic strategy. 
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The Boc-protected esters of α-amino acids were found to be the most suitable, cheap and 
readily available starting materials. The conversion of the α-amino acid esters 76a-c to the 
olefins 77a-c was already reported.84 This one-pot procedure is based on the reduction of the 
N-Boc-α-amino esters with diisobutylaluminium hydride (DIBAL) while avoiding the final 
product racemization. The resulting aluminoxyacetal formed in situ is directly treated with 
Wittig reagent to afford the desired chiral N-protected amines (Scheme 3.6). The fundamental 
benefit of this procedure is the preservation of the products chiral centre.84  
 
 
Scheme 3.6 Aluminoxyacetal formation in one-pot reduction Wittig olefination procedure.84 
 
The reaction was carried out following the literature procedure.84 Initially, the overall 
yields of 77 were below expectations. According to the procedure, 2 equivalents of the 
reducing agent DIBAL over 15 minutes were added drop-wise. Increasing the DIBAL 
addition time to 30 minutes led to yield improvement, however, only moderate amounts of the 
olefins 77a-c were eventually isolated (Scheme 3.7). Possible reduction to the corresponding 
alcohols, difficult detection of the products 77a-c during flash chromatography or cleavage of 
the Boc group on silicagel may be the cause of the limited yields. Nevertheless, the N-Boc 
protected olefins 77a-c were isolated with the optical rotation corresponding to the literature 
values.84 
 
Scheme 3.7 Reagents and conditions: (a) 1) DIBAL, toluene, -78 ºC, 1 h; 2) Ph3PCH2Br, t-BuOK, THF, -78 ºC 
1h to 50 ºC, 20 h. 
 Having the chiral N-tert-butylcarbamantes 77a-c available, the next step was N-Boc 
deprotection to access the chiral amines 45a-c, which could be reacted with the purine 49b 
(Scheme 3.5). The Boc group should be easily removed under acidic conditions. For this 
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reason, freshly generated HCl gas was passed through a solution of 77a-c in MeOH.18  
According to TLC the deprotection was completed in 50 minutes. Despite the promising 
reaction progress, this method was considered inconvenient. First of all an extensive amount 
of HCl gas has to be generated prior to the deprotection. The neutralisation of the significant 
HCl excess in the reaction mixture required an immense amount of saturated NaHCO3 
solution. For separation of the resulting inorganic residue and a polar amine 45a-c, arduous 
extraction was required to quantitatively transfer the product into the organic phase. In 
addition to this, due to the volatility, the free amines 45a-c were difficult to isolate in pure 
form and in acceptable yield. Subsequently, a more convenient way to achieve deprotection 
was sought in the literature, wherein the final deprotected products were isolated as 
ammonium hydrochloride salts.85 Instead of using the excess of hydrochloride gas, the 
deprotection was carried out with only 1.7 equivalent of a concentrated (37%) HCl solution, 
which facilitated the reaction workup. The resulting ammonium salts 78a-c were obtained in 
good yields (Scheme 3.8).   
 
Scheme 3.8 Reagents and conditions: (a) 1) HCl (g), MeOH, 20 min. at 0 ºC then r.t., 30 min 2) sat. NaHCO3; 
(b) HCl (aq. 37%), Acetone, Δ, 3 h. 
3.2.2 Application of the ammonium salts  
Substitution reactions carried out with ammonium salts and N-alkylated 6-
chloropurines are occasionally mentioned in the literature.86,87 The ammonium hydrochloride 
salt is converted by additional base into the amine in situ and the amine is then readily 
available for the nucleophilic aromatic substitution with the purine. In our particular case, 
pyridine was used for the reaction of purine 49b with salt 78a because pyridine with its basic 
properties could serve both as a solvent and as the base. The outcome of this reaction was 
rather surprising. First of all, the desired product 75a coming from the nucleophilic 
substitution was neither isolated nor detected during the reaction. Instead, a substantial 
amount of 7-allyl-7H-purin-6-amine (49a) was obtained as the major product. Most 
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importantly, the pyridinium salt 79a was successfully isolated and characterised (Scheme 
3.9). 
 
Scheme 3.9 Reagents and conditions: (a) pyridine, 100 ºC, 16 h. 
In order to compare this unexpected result to the previous report, where the pyridine 
was used in similar case,18 two parallel reactions were carried out.  In the first case, material 
49b was treated with 10 equivalents of allylamine (45d) in refluxing pyridine, while in the 
second case, 5 equivalents of allyammonium hydrochloride (78d) were used (Scheme 3.10). 
The equivalents of the allylammonium salt to 49b were purposefully decreased, to make the 
procedure more economically acceptable for the future application of the chiral ammonium 
salts 78a-c. The reaction of 49b with allylamine 45d was easily reproducible and the expected 
product 72 was isolated in high yield. In contrast to this, when the allyammonium 
hydrochloride was brought to reaction, only products 49a and salt 79b were observed on 
TLC. The 1H NMR spectra of the crude product indicated formation of salt 79b in 
approximately 1:1 relative ratio to the product 49a. The reaction gave the 7-allyl-7H-purin-6-
amine (49a) in 40% yield. The compound 79b was not successfully isolated (Scheme 3.10). 
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Scheme 3.10 Reagents and conditions: (a) pyridine, 100 ºC, 16 h. 
The formation of the pyridinium salts 79 probably corresponds to what was discovered 
by Zincke et al. in early 1900's.88,89 Zincke reported the formation of the pyridinium salts as 
well as the following reaction of these salts with amines. Studies of the mechanism revealed, 
that these reactions occur via pyridine ring-opening and reclosure (Scheme 3.11).90-92 The 
starting N-arylated pyridinium salt (Zincke salt) is obtained by the reaction of pyridine with 
2,4-dinitrochlorbenzene (80a). When the Zincke salt is exposed to an amine, the amine 
nitrogen is integrated into the heterocycle and 2,4-dinitroaniline (80b) is released. The Zincke 
reaction is used to synthesize pyridinium salts that cannot be prepared by a direct N-
functionalization of the pyridine.93  
 
Scheme 3.11 The Zincke reaction.90,92 
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For our particular situation it is possible, that before the allylammonium hydrochloride 
is neutralised to the amine in pyridine solution, the chloropurine 49b reacts with the pyridine 
itself forming the pyridinium salt 81. Subsequently, this Zincke intermediate reacts with 
amine 45 which is formed in situ during the reaction progress. This gives the product 49a and 
the corresponding pyridinium salt 79 (Scheme 3.12).  
 
 
Scheme 3.12 Possible formation of 49a and 79 via Zincke reaction. 
This hypothesis is further supported by two additional facts. First of all, the formation 
of the pyridinium salts from chloropurines is reported.94-96 Secondly, a very similar reaction 
pathway employing the Zincke-type intermediate was utilized  for the synthesis of 
isoguanosine 82b (Scheme 3.13).97  
 
Scheme 3.13 Reagents and conditions: (a) pyridine/water 1:1, 50 ºC, 2 h; (b) aq. NH3 (32%),  50 ºC, 5 h.97 
In our case, the formation of the unwanted Zincke intermediate 81 may probably be 
prevented, if the ammonium salt is treated only with pyridine in the absence of the substrate 
49b, releasing the free amine 45. After the complete neutralisation, the subsequently added 
chloropurine 49b has an opportunity to react with the amine 45 instead of the pyridine. 
However, we generally decided to exclude pyridine as a solvent of choice in the synthesis of 
75a-c. 
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 The application of another solvent was investigated and n-BuOH was chosen (Scheme 
3.14). To test the performance of the reaction, model syntheses were carried out. Allylamine 
or allylammonium chloride (78d) was refluxed with 49b in n-BuOH, in the presence of the 
sterically hindered non-nucleophilic base DIPEA (Table 3.1). The initial results were very 
promising. Switching from pyridine to n-BuOH resulted in an improved reaction progress. 
The product 72 from the reaction with allyl amine (45d) was obtained in high yield after only 
2 hours of reaction time (Table 3.1, entry 2). Furthermore, this procedure was also compatible 
with the allylammonium chloride (78d) and the product 72 was isolated in good yield (Table 
3.1, entry 3). 
 
 
Scheme 3.14 Reagents and conditions: (a) see Table 3.1. 
 
Table 3.1 Condensation of amines/ammonium salts with 49b 
Entry Substrate Equiv.a Solvent base Time [h] Yield [%]b  Prod. 
1 45d 10 Pyridine - 17 90 72 
2 45d 5 n-BuOH DIPEA 2 97 72 
3 78d 5 n-BuOH DIPEA 2 80 72 
4 78a 1.1 n-BuOH DIPEA 48 92 75a 
5 78b 1.1 n-BuOH DIPEA 48 98 75b 
6 78c 1.1 n-BuOH DIPEA 48 67 75c 
7 78c 3 n-BuOH DIPEA 24 93 75c 
a 1 equivalent of 49b used; bIsolated yield. 
 
The previously tested conditions were finally performed with the chiral ammonium 
salts 78a-c. Further decrease of the equivalents of 78a-c relative to 49b was attempted, which 
resulted in longer reaction time (Table 3.1, entries 4-6). Under these conditions, the products 
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75a and 75b were isolated in high yields. The product 75c was obtained with better yield, 
when the equivalents of 78c were increased from 1.1 to 3 (Table 3.1, entries 6 and 7).   
3.2.3 Double bond rearrangement under basic conditions  
Compounds 75a-c were conveniently isomerized to propenylpurines 46a-c in 
refluxing MeCN with K2CO3 (Scheme 3.15). All the intermediates 75a-c showed lower 
reactivity compared to the unsubstituted compound 72. While the isomerized product 1 was 
acquired within 17 h (Scheme 3.4), in case of 75a-c, the reaction required up to 72 h for 
completion. The N-prop-enyl purines 46a-c were obtained selectively as Z-isomers in good 
yields. 
 
 
Scheme 3.15 Reagents and conditions: (a) K2CO3, MeCN, Δ, 72 h. 
3.2.4 N-Protection attempts 
The next step in the synthetic sequence was the N-Boc protection of compounds 46a-c. 
The reduced reactivity of the analogue 1 with (Boc)2O was already known (Scheme 3.4)18 and 
a comparably slow progress was expected also for the reaction with the purines 46a-c. 
Unfortunately, the initial attempt to introduce Boc groups to the secondary amines 46b-c, 
applying the same conditions as before, gave no product (Scheme 3.16). The starting material 
46b was recovered virtually intact after 4 days (Table 3.2, entry 1). Several other literature 
conditions for Boc-protection were investigated.18,98-101 Additional base (Table 3.2, entries 2 
and 3), elevated reaction temperature (Table 3.2, entries 4 and 5) or carrying out the reaction 
with (Boc)2O in the absence of the solvent (Table 3.2, entries 6 and 7) did not lead to any 
conversion towards the protected products 67. In one particular case (Table 3.2, entry 6), 10 
molar% of iodine were used as a catalyst for the Boc-protection. It is reported, that iodine in 
combination with Boc2O should be compatible with N-allylic substrates.100 Unfortunately, 
exposing compound 46c to these conditions lead to formation of several unknown side-
products and only 30% of the starting material 46c was recovered. 
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Scheme 3.16 Reagents and conditions: (a) Boc2O, see Table 3.2. 
 
Table 3.2 Overview of the conditions for N-Boc protection of 46b-c 
Entry s.m. Solv. (Boc)2Oa Cat/Base T 
Time 
[h] 
rec. 
[%]b 
118 46b MeCN 4.3 DMAP(1eq.)18 r.t. 96 93 
298 46b DCM 3 DMAP (1eq.)/Et3N (1eq.)98 r.t. 24 82 
398 46c DCM 3 DMAP (1eq.)/Et3N (1eq.)98  r.t. 24  93 
499 46b THF 2 DMAP (0.1 eq.)99  Δ 24 70 
599 46c THF 2 DMAP (0.1 eq.)99 Δ 24 80 
6100 46c Neat 3.3 I2 (0.1 eq)100 r.t. 72 30 
7101 46c Neat 4.4 DMAP (0.01 eq.)101 r.t. 24  100 
aEquivalents of (Boc)2O to 46; bRecovered starting material. 
 
The additional substitution on the α-position in the N6-allyl chain turned the amines 
46b-c into very challenging substrates. The secondary amine group attached to the electron 
withdrawing purine is a very poor nucleophile. Moreover, the sterical hindrance of the 
reaction centre by the α-substituents on N6-allyl chain might cause the overall drop in the 
reactivity. Realizing the limited reactivity of 46b-c towards N-protection as well as the 
necessity to introduce a bulky protection group, we investigated the possibility of applying the 
pivaloyl group.  The steric bulk of the pivaloyl protecting group is very similar to the Boc 
group and its application in RCM is known.102 Moreover, it can be introduced using the much 
more reactive pivaloyl chloride. Thus, a model synthesis with 72 and pivaloyl chloride was 
carried out using a literature procedure103 (Scheme 3.17). Also in this case, the reaction 
resulted in no conversion to the desired N-alkylated product 84. Elevated temperature104 or a 
continuous addition of the pivaloyl chloride into the reaction mixture did not give any 
conversion to the N-alkylated product 84. 
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Scheme 3.17 Reagents and conditions: (a) DMAP, DIPEA, DCM, 0 ºC to r.t., 16 h; (b) DIPEA, DCM, 0 ºC to Δ, 
16 h. 
One of the main reasons, why the N-protecting groups are introduced, is to avoid a 
poisoning of the ruthenium catalyst by the amine nitrogen from the substrate (Section 
3.1.1).73,74 Resistance of the compounds 46b-c to any of the attempted protection conditions 
indicated, that poor nucleophilicity and sterical hindrance of the N6-nitrogen might prevent 
this potential poisoning and the desired RCM could take place with unprotected 46b-c.  
Regrettably, when the most sterically hindered compounds 46b or 46c were brought to the 
RCM conditions, the ring-closing did not occur even with extended reaction time. The 
unreacted starting materials 46b and 46c were recovered (Scheme 3.18). 
 
Scheme 3.18 Reagents and conditions: (a) Hoveyda-Grubbs II, DCE, Δ, 5 h. 
The unsuccessful N-protection of the compounds 46b-c was an unexpected 
complication in the designed synthetic sequence. From previous experience, the installation of 
a proper protecting group is the last important step before the key RCM could be approached. 
Consequently, we decided to change the approach at this point and we tried to obtain N-Boc 
protected intermediates 67a-c in another fashion. This alternative synthetic strategy, based on 
a copper catalysed C-N bond formation and ruthenium promoted double bond migration is 
discussed in the following chapter. However we did not turn away from the N-protection 
investigation completely. The further discussion regarding the employment of the N-
protection in the synthetic pathway is shown in section 4.2.5, page 64. 
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3.3 Summary and conclusion 
 The first attempt towards the synthesis of the asmarine analogues 47a-c, derived from 
α-amino acids was presented. N-Boc protected esters of the α-amino acids phenylalanine, 
valine and leucine were chosen as the starting point. The chiral N-Boc protected allylic 
amines 77a-c were prepared without racemization and successfully deprotected under acidic 
conditions. The resulting chiral allylic amines were isolated in high yields as the 
hydrochloride salts 78a-c. After initial complications, the chiral allylammonium salts 78a-c 
were successfully employed in the synthesis of products 75a-c. The previously discovered 
double bond migration under basic conditions was performed with compounds 75a-c. All 
corresponding rearranged products 46a-c were conveniently obtained exclusively as Z-
isomers in good yields. Unfortunately, all the attempts to introduce a protecting group to the 
N6-nitrogen of 46b-c were not successful. The resistance towards the N-protection is probably 
caused as a combination of a poor nucleophilicity and sterical hindrance of the N6-nitrogen of 
the compounds 46. 
3.4 Experimental 
The NMR data for purines 72, 73a-c and 46a-c possessing two allylic side chains are 
presented according to the description in Figure 3.3. The protons from the terminal double 
bond, which show separate signals in 1H NMR, are presented as HA in =CH2 and HB in =CH2 
for the trans and cis proton, respectively. 
 
 
Figure 3.3 Description of the allyl/prop-1-en-3-yl side chain in the NMR spectra. 
(S,Z)-N-(1-phenylbut-3-en-2-yl)-7-(prop-1-enyl)-7H-purin-6-amine (46a) 
 (S)-7-allyl-N-(1-phenylbut-3-en-2-yl)-7H-purin-6-amine 75a (0.17 mmol, 52 mg) and K2CO3 
(0.40 mmol, 54 mg) were stirred at reflux in MeCN (3.2 mL) for 72 h under N2. The reaction 
mixture was cooled to ambient temperature and filtered. The solvent was removed in vacuo 
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affording the desired product 46a in quantitative yield; yield 52 mg (100%, E/Z = 1˂99), 
yellow oil. Z-isomer: 1H NMR (CDCl3, 400 MHz) δ 1.53 (dd, J1 = 7.1 Hz, J2 = 1.6 Hz, 3H, 
CH3-1), 2.94-3.09 (m, 2H, CH2-4'), 5.01 (bd, J = 7.9 Hz, 1H, NH), 5.08 (d, J = 17.7 Hz, 1H, 
HA in =CH2-1'), 5.14 (d, J = 10.7 Hz, 1H, HB in =CH2-1'), 5.23 (m, 1H, CH-3'), 5.90-6.03 (m, 
2H, CH=-2' and =CH-2), 6.68 (d, J = 7.8 Hz, 1H, NCH-3), 7.14-7.30 (m, 5H, Ph), 7.74 (s, 1H, 
H-8), 8.52 (s, 1H, H-2); 13C NMR (CDCl3, 75 MHz) δ 12.2 (CH3-1), 40.6 (CH2-4'), 52.4 (CH-
3'), 111.5 (C-5), 115.1 (=CH2-1'), 122.7 (NCH-3), 126.8, 128.4 and 129.6 (Ph), 132.0 (=CH-
2), 136.8 (Ph), 137.8 (CH= 2'), 143.4 (C-8), 150.4 (C-6), 153.7 (C-2), 159.2 (C-4); MS (EI) 
m/z (rel. int.) 305 (9, M+), 214 (100), 91 (7), 56 (10); HRMS (EI) C18H19N5 requires 
305.1640, found 305.1645; [ɑ]D20 = 23 º. 
(S,Z)-N-(4-methylpent-1-en-3-yl)-7-(prop-1-enyl)-7H-purin-6-amine (46b) 
(S)-7-allyl-N-(4-methylpent-1-en-3-yl)-7H-purin-6-amine (75b) (0.450 mmol, 117 mg) and 
K2CO3 (1.03 mmol, 143 mg) were stirred at reflux in MeCN (10 mL) for 72 h under N2. The 
reaction mixture was cooled down to ambient temperature and filtered. Solvent was removed 
in vacuo. The residue was purified by flash chromatography using MeOH/CH2Cl2  (1:32); 
yield 81 mg (70%, E/Z = 1˂99), yellow amorphous solid, mp 93-95 °C. 1H NMR (CDCl3, 300 
MHz) δ 0.89 (d, J = 6.8 Hz, 3H, CHMe2), 0.90 (d, J = 6.8 Hz, 3H, CHMe2), 1.69 (dd, J1 = 7.0 
Hz, J2 = 1.8 Hz, 3H, CH3-1), 1.93 (m, 1H, CHMe2), 4.80 (m, 1H, CH-3'), 5.05-5.19 (m, 3H, 
=CH2-1', NH), 5.80 (m, 1H, CH=-2'), 6.20 (m, 1H, =CH-2), 6.90 (dd, J1 = 7.9 Hz, J2 = 1.9, 
1H, NCH-3) 7.74 (s, 1H, H-8), 8.45 (s, 1H, H-2); 13C NMR (CDCl3, 75 MHz) δ 12.3 (CH3-1), 
18.0 (CHMe2), 18.4 (CHMe2), 31.9 (CHMe2), 56.9 (CH-3'), 111.4 (C-5), 115.6 (=CH2-1'), 
123.1 (NCH-3), 132.3 (=CH-2), 136.5 (CH=-2'), 143.3 (C-8), 151.1 (C-6), 153.5 (C-2), 158.8 
(C-4); MS (EI) m/z (rel. int.) 257 (10, M+), 242 (16), 214 (100), 200 (10); HRMS (EI) 
C14H19N5 requires 257.1640, found 257.1633; [ɑ]D20 = 58 º. 
(S,Z)-N-(5-methylhex-1-en-3-yl)-7-(prop-1-enyl)-7H-purin-6-amine (46c) 
(S)-7-allyl-N-(5-methylhex-1-en-3-yl)-7H-purin-6-amine (75c) (0.730 mmol, 198 mg) and 
K2CO3 (1.68 mmol, 232 mg) were stirred at reflux in MeCN (13.5 mL) for 72 h under N2. The 
reaction mixture was cooled down to ambient temperature and filtered. The solvent was 
removed in vacuo and the crude product was purified by flash chromatography using 
MeOH/CH2Cl2 (1:49); yield 145 mg (75%, E/Z = 1˂99), orange amorphous solid, mp 70-73 
°C. 1H NMR (CDCl3, 300 MHz) δ 0.92 (d, J = 6.5 Hz, 3H, CHMe2), 0.93 (d, J = 6.5 Hz, 3H, 
CHMe2), 1.48 (m, 2H, CH2-4'), 1.61-1.71 (m, 4H, CH3-1, CHMe2), 4.96-5.18 (m, 4H, =CH2-
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1', CH-3', NH), 5.83 (m, 1H, CH=-2'), 6.19 (m, 1H, =CH-2), 6.93 (dd, J1 = 7.7 Hz, J2 = 1.8 
Hz, 1H, CH-3), 7.78 (s, 1H, H-8), 8.49 (s, 1H, H-2); 13C NMR (CDCl3, 75 MHz) δ 12.4 (CH3-
1), 22.5 (CHMe2), 22.7 (CHMe2), 25.0 (CHMe2), 44.4 (CH2-4'), 50.5 (CH-3'), 111.3 (C-5), 
114.7 (=CH2-1'), 123.0 (NCH-3), 130.5 (=CH-2), 138.7 (CH=-2'), 143.5 (C-8), 150.7 (C-6), 
153.4 (C-2), 158.6 (C-4); MS (EI) m/z (rel. int.) 271 (13, M+), 256 (25), 228 (43), 214 (100), 
200 (51); HRMS (EI) C15H21N5 requires 271.1797, found 271.1798; [ɑ]D20 = 22 º. 
N,7-Diallyl-7H-purin-6-amine (72) 
Allylamine (12.8 mmol, 1.00 mL) and DIPEA (5.1 mmol, 0.90 mL) were stirred in n-BuOH 
(14 mL) at ambient temperature under N2 for 1 h prior to use. 7-Allyl-6-chloro-7H-purine 
(49b) was added (2.60 mmol, 500 mg) and the reaction mixture was refluxed for 2 h. The 
mixture was concentrated in vacuo. The crude product was purified by flash chromatography 
using MeOH/CH2Cl2 (1:19); yield 540 mg (97%), off-white solid, mp 140-143 °C (Lit18 140-
143 °C). Spectral data were in a good agreement with those reported before.18 
(S)-7-Allyl-N-(1-phenylbut-3-en-2-yl)-7H-purin-6-amine (75a)  
(S)-1-phenylbut-3-en-2-aminium chloride 78a (1.10 mmol, 202 mg) and DIPEA (3.10 mmol, 
0.540 mL) were stirred in n-BuOH (5.4 mL) at ambient temperature under N2 for 10 min prior 
to use. 7-Allyl-6-chloro-7H-purine (49b) (1.00 mmol, 195 mg) was added and the reaction 
mixture was refluxed for 48 h. The mixture was evaporated in vacuo and the product was 
purified by flash chromatography using MeOH/CH2Cl2 (1:49); yield 280 mg (92%), yellow 
oil. 1H NMR (CDCl3, 300 MHz) δ 2.98 (m, 2H, CH2-4'), 4.57-4.86 (m, 3H, NCH2-3, HA in 
=CH2-1), 4.90 (bd, J = 8.63 Hz, 1H, NH), 4.97-5.18 (m, 3H, HB in =CH2-1, =CH2-1'), 5.26 
(m, 1H, CH-3'), 5.87 (m, CH=-2, CH=-2'), 7.19 (m, 5H, Ph), 7.79 (s, 1H, H-8), 8.46 (s, 1H, 
H-2); 13C NMR (CDCl3, 75 MHz) δ 40.5 (CH2-4'), 49.3 (NCH2-3), 55.4 (CH-3'), 111.9 (C-5), 
115.1 (=CH2-1'), 119.1 (=CH2-1), 126.7, 128.3 and 129.7 (Ph), 133.0 (CH=-2), 136.9 (Ph), 
137.7 (CH=-2'), 144.6 (C-8), 149.8 (C-6) 153.3 (C-2), 160.0 (C-4); MS (EI) m/z (rel. int.) 305 
(9, M+), 214 (100), 174 (6), 91 (7); HRMS (EI) C18H19N5 requires 305.1640, found 305.1646; 
[ɑ]D20 = 45 º.  
(S)-7-allyl-N-(4-methylpent-1-en-3-yl)-7H-purin-6-amine (75b) 
Ammonium chloride 78b (1.10 mmol, 150 mg) and DIPEA (3.10 mmol, 500 μl) were stirred 
in n-BuOH (5.4 mL) at ambient temperature under N2 for 1 h prior to use. 7-Allyl-6-chloro-
7H-purine (49b) (1.00 mmol, 195 mg) was added and reaction mixture was refluxed for 48 h. 
The mixture was evaporated in vacuo and purified by flash chromatography using 
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MeOH/CH2Cl2 (1:19); yield 194 mg (98%), beige solid, mp 115-117 °C. 1H NMR (CDCl3, 
300 MHz) δ  0.90 (d, J = 6.8 Hz, 3H, CHMe2), 0.92 (d, J = 6.8 Hz, 3H, CHMe2), 1.84-2.00 
(m, 1H, CHMe2), 4.84 (m, 1H, CH-3'), 4.91 (m, 2H, NCH2-3), 5.00 (bd, J = 8.8 Hz, 1H, NH), 
5.09 (m, 2H, =CH2-1'), 5.18 (dt, J1 = 17.4, J2 = 2.0 Hz, 1H, HA in =CH2-1), 5.44 (dt, J1 = 10.5, 
J2 = 1.8 Hz, 1H, HB in =CH2-1), 5.81 (m, 1H, CH=-2'), 6.16 (m, 1H, CH=-2), 7.83 (s, 1H, H-
8), 8.44 (s, 1H, H-2); 13C NMR (CDCl3, 75 MHz) δ 18.3 (CHMe2), 18.5 (CHMe2), 31.9 
(CHMe2), 49.4 (NCH2-3), 57.2 (CH-3'), 111.9 (C-5), 115.7 (=CH2-1'), 119.2 (=CH2-1), 133.3 
(CH=-2), 136.5 (CH=-2'), 144.6 (C-8), 150.4 (C-6), 153.4 (C-2), 160.1 (C-4); MS (EI) m/z 
(rel. int.) 257 (12, M+), 242 (23), 214 (100), 200 (15), 174 (13), 56 (9), 41 (13); HRMS (EI) 
C14H19N5 requires 257.1640, found 257.1645; [ɑ]D20 = 55 º. 
(S)-7-Allyl-N-(5-methylhex-1-en-3-yl)-7H-purin-6-amine (75c) 
(S)-5-methylhex-1-en-3-aminium chloride 78c (2.90 mmol, 427 mg) and DIPEA (6.62 mmol, 
1.13 mL) were stirred in n-BuOH (25 mL) at ambient temperature under N2 for 1 h prior to 
use. 7-Allyl-6-chloro-7H-purine (49b) (0.82 mmol, 160 mg) was added and the reaction 
mixture was refluxed for 24 h. The mixture was concentrated in vacuo. The crude product was 
purified by flash chromatography using MeOH/CH2Cl2 (1:49); yield 207 mg (93%), yellow 
oil. 1H NMR (CDCl3, 300 MHz) δ 0.84 (d, J = 6.5 Hz, 3H, CHMe2), 0.86 (d, J = 6.5 Hz, 3H, 
CHMe2), 1.39 (m, 2H, CH2-4'), 1.62 (m, 1H, CHMe2), 4.85-5.17 (m, 7H, CH-3', =CH2-1', 
NCH2-3, NH, HA in =CH2-1) 5.36 (dt, J1 = 10.5 Hz, J2 = 2.0 Hz, 1H, HB in =CH2-1), 5.77 (m, 
1H, CH=-2'), 6.05 (m. 1H, CH=-2), 7.80 (s, 1H, H-8), 8.39 (s, 1H, H-2); 13C NMR (CDCl3, 75 
MHz) δ 21.3 (CHMe2), 22.1 (CHMe2), 24.7 (CHMe2), 44.3 (CH2-4'), 49.4 (NCH2-3), 50.5 
(CH-3'), 111.7 (C-5), 114.3 (=CH2-1'), 119.0 (=CH2-1), 133.5 (CH=-2), 138.7 (CH=-2'), 
144.6 (C-8), 150.2 (C-6), 153.1 (C-2), 159.4 (C-4); MS (EI) m/z (rel. int.) 271 (6, M+), 256 
(27), 228 (44), 214 (100), 200 (54), 174 (18). ); HRMS (EI) C15H21N5 requires 271.1797, 
found 271.1794; [ɑ]D20 = 26 º. 
1-(1-Phenylbut-3-en-2-yl)pyridin-1-ium chloride (79a) 
7-Allyl-6-chloro-7H-purine (49b) (0.25 mmol, 49 mg) was refluxed in pyridine (3.0 mL) with 
(S)-1-Phenylbut-3-en-2-aminium chloride 78a (1.14 mmol, 282 mg) for 20 h. The mixture 
was concentrated in vacuo. The crude products were separated by flash chromatography on 
silica using MeOH/CH2Cl2 (1:9); yield 23 mg, (7%), off-white solid, mp 203 °C decomp. 1H 
NMR (DMSO-d6, 300 MHz) δ 3.41-3.59 (m, 2H, CH2-1), 5.50 (m, 2H, =CH2-4), 5.92 (dt, J1 
= 9.1 Hz, J2 = 6.4 Hz, 1H, NCH-2), 6.33-6.44 (m, 1H, CH=-3), 7.15-7.25 (m, 5H, Ph), 8.13 
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(dd, J1 = 7.7 Hz, J2 = 6.5 Hz, 2H, H-3 + H-5), 8.58 (tt, J1 = 7.7 Hz, J2 = 1.3 Hz, 1H, H-4), 
9.25 (dd, J1 = 6.5 Hz, J2 = 1.3 Hz, H-2 + H-6); 13C NMR (DMSO-d6, 75 MHz) δ 38.4 (CH2-
1), 72.8 (NCH-2), 121.3 (=CH2-4), 126.5 (Ph), 127.8 (C-3+C-5), 128.00 and 128.5 (Ph), 
133.9 (CH=-3), 134.9 (Ph), 143.2 (C-2+C-6), 145.8 (C-4); MS (ESI) m/z (rel. int.) 210 
[M+1]+; HRMS (EI) C15H16N requires 210.1277, found 210.1277. 
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Chapter 4  
Ruthenium promoted double bond migration and copper 
mediated C-N bond formation in the synthesis towards 
asmarines 
4.1 Introduction 
Facing serious problems with the N-Boc protection (Section 3.2.4, page 38), we had to 
redesign the initial reaction pathway. The Boc group of intermediate 77a-c was removed in 
the second step of the original strategy in order to allow a nucleophilic substitution with the 6-
chloropurine 49b. Unfortunately, later in the sequence we encountered difficulties trying to 
reintroduce the Boc group to obtain the product 67a-c (Scheme 4.1). Therefore, another 
strategy employing carbon-nitrogen (C-N) bond formation was explored. The primary 
objective of this alternative approach was to investigate, whether the C-N bond between a 
suitable halopurine and the carbamates 77a-c could be formed directly, without previous Boc-
deprotection (Scheme 4.1). To complete this reaction pathway leading to the RCM precursor 
67, conditions for N-7 allyl rearrangement were investigated. 
 
Scheme 4.1 Strategies towards the N-Boc protected products 67a-c. 
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4.1.1 Methods for C-N bond formation  
4.1.1.1 Nucleophilic substitution with N-sodium carbamates 
Formation of the C-N bond using N-protected amines can be achieved in a relatively 
facile manner. There are examples known, wherein Boc-protected amines are taking part in 
nucleophilic substitutions via N-sodium carbamate formation.105,106 The apparent benefit of 
this method was demonstrated in the synthesis of N-alkoxyaminopyridines 88.107 The typical 
synthetic procedure consists of two steps, starting with the treatment of an appropriate chloro-
pyrimidine with a free amine. After SNAr, the N-alkoxycarbonylation should take place. In 
contrast to this, taking advantage of the N-sodium carbamate formation, the whole process can 
be covered in single step with good yield of the final products (Scheme 4.2).107,108  
 
Scheme 4.2 Reagents and conditions: (a) NaH, DMF, r.t., 0.5 to 22 h.107 
Interestingly, this method was successfully employed in amidation of 6-halopurines 90 
(Scheme 4.3).109 
 
Scheme 4.3 Reagents and conditions: (a) NaH, DMF, 0 ºC to r.t., 2 to 4 h.109 
Despite the advantages, there is an apparent general limitation of this type of SNAr. The 
substrate leaving group has to be present either in α or γ position on an appropriate N-
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heterocyclic core or on an aromatic ring in ortho or para position relative to the electron 
withdrawing group.110 Nevertheless, considering the similarity of this approach with the aim 
of our investigation, we decided to examine this strategy (Section 4.2.1). 
4.1.1.2 Hartwig-Buchwald coupling  
One of the sophisticated methods for C-N bond formation is the palladium catalysed hetero 
cross-coupling, which was developed by Hartwig and Buchwald. This method was originally 
designed for the coupling of primary amines with aromatic bromides 92 (Scheme 4.4).111,112  
 
 
Scheme 4.4 Aryl bromides in the Hartwig-Buchwald coupling with amines. 
The scope if this reaction was later on extended, hence the Hartwig-Buchwald coupling is 
now commonly performed with a broad range of amines or anilines and aryl halides. This 
coupling is manly suitable for electron poor aryl halides.112 In our particular case, we were 
interested in this type of reactions since the application of various amides or carbamates in 
Hartwig-Buchwald coupling is known (Scheme 4.5).110,113-115  
 
Scheme 4.5 Reagents and conditions: (a) Pd(OAc)2, Xanthphos, Cs2CO3, dioxane, 110 ºC, 20 h.110,115 
Most importantly, the Pd catalysed amidation found its application in purine chemistry. 
Several N-9 unprotected 6-halopurines 100116,117 or N-alkyl 6-halopurines 102109,116 were 
successfully employed in this Hartwig-Buchwald protocol. 
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Scheme 4.6 Reagents and conditions: (a) Pd3(dba)2, Xanthphos, Cs2CO3, dioxane, 130 ºC, 8 to 24 h;116 (b) 
Pd3(dba)2, Xanthphos, Cs2CO3, dioxane, 100 ºC, 1 h.109 
4.1.1.3 Goldberg reaction 
For the substrates which are incompatible with the Hartwig-Buchwald coupling, the 
Goldberg reaction118 is usually a suitable alternative.119 The Goldberg reaction is a copper 
catalysed amidation of aryl or heteroaryl halides (Scheme 4.7).118 The original application of 
this method was rather limited due to the requirement of elevated reaction temperatures and 
large amounts of copper reagents. On top of that, the copper coupling occurred only in polar 
solvents, giving moderate yields.119,120  
 
Scheme 4.7 Copper catalysed amidation of aryl halides.   
Recent development of suitable ligand systems (Scheme 4.8) facilitated the reaction 
conditions and thus opened a broad employment of the Goldberg reaction in organic 
synthesis.119-122 The most important advantage of this method is its wide application with 
different amides and electron rich aryl halides. Moreover, the reaction is carried out with 
inexpensive catalysts such as copper salts.  
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Scheme 4.8 Chelating ligands in the Goldberg reaction.122 
The tert-butyl carbamates can be problematic substrates in some cases.123 However, the 
amidation using Boc-protected amines is reported (Scheme 4.9).119,123 The Goldberg reaction 
was successfully utilised in our synthetic strategy (Section 4.2.2). 
 
 
Scheme 4.9 Reagents and conditions: (a) CuI, N1,N2-dimethylethane-1,2-diamine, K2CO3, toluene, 110 ºC, 20 
h;123 (b) CuI, (1S,2S)-cyclohexane-1,2-diamine, K3PO4, toluene, 110 ºC, 25 h.119 
 
Chapter 4 
 
 
51 
 
4.2 Results and discussion 
4.2.1 Attempts for the application of N-sodium carbamate  
Initially, a method for establishing the C-N bond via N-sodium carbamate was 
explored (Scheme 4.10). Model reactions using 49b and tert-butyl allylcarbamate were 
carried out following literature procedures. tert-Butyl allylcarbamate was stirred with NaH in 
dry DMF for 1 hour107,108 prior to addition of 7-allyl-6-chloro-7H-purine (49b). Formation of 
hydrogen gas in the reaction mixture indicated successful generation of the N-sodium allyl 
carbamate. Purine 49b was subsequently added at -25 ºC and the reaction was allowed to 
warm up to ambient temperature. Regrettably, no product was observed after 24 h and 50% of 
the starting 49b was recovered (Scheme 4.10). Based on another report,106 the solution of N-
sodium carbamate was prepared in THF at 0 ºC. Subsequently, the purine 3a was added and 
the reaction was allowed to proceed at ambient temperature. This attempt resulted in the 
degradation of the substrate 49b after 4 h, as judged by TLC. Unfortunately, the chloropurine 
49b does not seem to be compatible with the reaction conditions. Since no conversion towards 
desired N-Boc protected product 112 was achieved by deprotonation of tert-butyl 
allylcarbamate 77d we had to focus on the investigation of the hetero cross couplings.  
 
Scheme 4.10 Regents and conditions: (a) NaH, DMF, -25 ºC to r.t., 24 h;108 (b) NaH, THF, 0 ºC to r.t., 4 h. 
4.2.2 Investigation of the transition metal catalysed C-N bond formation 
The Pd catalysed Hartwing-Buchwald and Cu promoted Goldberg reaction conditions 
were examined. The ligands used in the reactions are depicted in Figure 4.1. 
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Figure 4.1 Ligands used in C-N coupling reactions. 
First we attempted the coupling of 7-allyl-6-chloro-7H-purine (49b) and carbamate 
77d under Hartwig-Buchwald conditions, using Pd(Ac)2 and the ligand 113110,115 (Scheme 
4.11). This reaction did not lead to any observable conversion and we switched our attention 
to the copper mediated coupling reactions. 
 
Scheme 4.11 Reagents and conditions: Pd(Ac)2, Cs2CO3, dioxane, 110 ºC, 24 h. 
Unfortunately, the initial results from the copper mediated Goldberg reaction were 
also not promising. In the beginning of our investigation, we tried to follow the literature 
procedures for the amidation of various aryl iodides, wherein a ligand (1S,2S)-cyclohexane-
1,2-diamine (114a) was used.119,121,124 These coupling conditions were applied to 7-allyl-6-
chloro-7H-purine (49b) (Scheme 4.12 and Scheme 4.13) to explore, whether the reactivity of 
49b can be comparable to the reactivity of the reported aryl iodides. Regrettably, the ligand 
114a, present in reaction mixture, reacted completely with the chloropurine 49b by SNAr and 
the hetero cross-coupling did not take place. In addition, the substitution was followed by 
migration of the double bond on the 7-allyl side chain. The reaction yielded 99% of the dimer 
115 (Scheme 4.12).  
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Scheme 4.12 Reagents and conditions: CuI, K3PO4, dioxane, 110 ºC sealed tube, 24 h. 
 The coupling reaction was also attempted with the non-nucleophilic ligand 1,10-
phenanthroline (114b).121,125 The desired C-N coupling did not take place here either. Instead, 
an unexpected side reaction leading to the by-product 116 occurred (Scheme 4.13). The minor 
formation of 116 could be explained by presence of moisture in the reaction mixture. The 
desired product 112 was not observed and 37% of the starting 49b was recovered. 
 
Scheme 4.13 Reagents and conditions: CuI, Cs2CO3, dioxane, 110 ºC sealed tube, 24 h. 
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 Since the chloropurine 49b showed no reactivity in the attempted copper coupling 
reactions, we tried to explore, whether the coupling will take place if the chlorine in the C-6 
position of the substrate will be replaced by iodine. For this reason, a suitable approach to 
obtain the iodo analogue 49d was investigated (Scheme 4.14).  Iodination of chloropurines is 
usually performed with hydroiodic acid (47%) or with combination of hydroiodic acid and 
potassium or sodium iodide. This halogen exchange procedure is reported both with alkyl 
purines,126,127 as well as with free purine bases.128 In our particular case the allyl chain in 49b 
cannot be preserved under the iodination conditions. Thus, the starting 6-iodo-9H-purine (6d) 
had to be synthesized first. A treatment of chloropurine 6b with hydroiodic acid128 gave high 
yield of the iodopurine 6d (Scheme 4.14). The product 49d was subsequently obtained in 
good yield from the regioselective allylation of 6d (Scheme 4.14, see also Section 2.2.2, page 
20). 
 
Scheme 4.14 Reagents and conditions: HI (47%), 0 ºC, 3 h; (b) methylaquacobaloxime, allyliodide, MeCN, r.t., 
120 h. 
 Having decent amounts of iodopurine 49d readily available, we were focused on the 
investigation of the Cu mediated C-N coupling. A series of test scale reactions were prepared 
and the conversion towards 112 was monitored by 1H NMR (Scheme 4.15, Table 4.1). 
Performing the coupling with compound 49d led to the formation of product 112 for the first 
time. Unfortunately, the unwanted dimer 116 was also initially detected (Table 4.1, entries 1-
4). Setting up the reaction under the inert atmosphere of a glovebox prevented a further 
occurrence of by-product 116. Moreover, additional improvement of the reaction progress 
was achieved by refluxing in THF in place of dioxane (Table 4.1, entries 4-6). A notable 
complication in this reaction procedure is the separation of substrate 49d and product 112. 
Both compounds possess very similar Rf values, thus purification by column chromatography 
was fairly difficult and the product was not isolated pure from the initial experiments (Table 
4.1, entry 1-5). Finally, when using a slow gradient elution, the product 112 was obtained in a 
pure form and acceptable yield (Table 4.1, entry 6). Higher conversion in this case helped to 
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facilitate the purification. In conjunction with previous attempts, C-N coupling did not take 
place with chloropurine 49b (Table 4.1, entry 7).  
 
Scheme 4.15 Reagents and conditions: (a) CuI, 1,10-phenanthroline; for solvents, temperature and time (see 
Table 4.1).  
Table 4.1 Cu coupling with halo-purines 49d and 49b 
Entry Subs. solvent T [°C] 
time 
[h] 
Conversion [%]a 
 
112 116 
1 49d dioxane 110 °C 24 20 30 sealed tube 
2 49d dioxane r.t. to 80 °C 55 35 7 sealed tube 
3 49d THF 70 °C 4 15 3 sealed tube 
4 49d THF Δ 16 60 8  
5 49d THF Δ 24 45 n.d.b  
6 49d THF Δ 48 60 n.d. Yield 56% 
7 49b THF Δ 48 n.d. n.d. 
aDetermined by 1H NMR of the crude product; bNot detected. 
4.2.3 Development of the method for the double bond migration 
To obtain the 7-membered ring by RCM, a double bond migration has to be employed 
in the synthetic sequence (see Chapter 3). Due to the successful finding of suitable C-N 
coupling conditions (Section 4.2.2), there are two possible pathways towards the RCM 
precursor 73 (Scheme 4.16). First of all, we wanted to examine, whether the coupling product 
112 could be rearranged to the desired product 73. In this particular case the isomerisation has 
to be regioselective, taking place on the N-7 allyl chain only. Another possibility is to 
rearrange the 6-iodopurne 49d prior to copper coupling. 7-Allyl-6-iodo-7H-purine (49d) 
possess only one allyl side chain, thus no selective rearrangement would be required. Both 
synthetic routes were investigated. 
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Scheme 4.16 Two possible reaction pathways towards the RCM precursor 73 employing a sequence of C-N 
coupling and double bond migration. 
The primary research was focused on a rearrangement of the N-Boc protected compound 112 
under basic conditions (Scheme 4.18, Table 4.2). From previous experience18 it was known, 
that 7-allyl-purines 72 and 75a-c bearing a free -NH group on C-6 can be selectively 
isomerised to corresponding 7-(propen-1-yl) purines using K2CO3 in refluxing MeCN  
(Section 3.2.3, page 38, Scheme 3.15). Importantly, when the proton from the secondary 
amine (Z)-N-allyl-7-(prop-1-en-1-yl)-7H-purin-6-amine (72) was replaced by a methyl group, 
a considerable decrease of the isomerisation was noted earlier (Scheme 4.17).18  
 
Scheme 4.17 Reagents and conditions: (a) K2CO3, MeCN, Δ; (b) K2CO3, n-BuOH, Δ.18 
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The same decrease in reactivity was observed for the rearrangement of the N-Boc protected 
compound 112. Inorganic carbonates or phosphates as well as elevated reaction temperatures 
were used, but the migration did not occur (Table 4.2, entries 1-4). We also tried to achieve 
the rearrangement of 112 using the strong base t-BuOK.129 This reaction resulted in partial 
decomposition of 112 (Table 4.2, entry 5). Substrate 112 also showed limited stability when 
exposed to sodium hydride either at reflux or at ambient temperature (Table 4.2, entries 6 and 
7).  
 
Scheme 4.18 Reagents and conditions: (a) see Table 4.2. 
 
Table 4.2 attempts for base promoted rearrangement of 112 
Entry solvent base T time [h] 
recovered 112 
[%] 
1 MeCN K2CO3 Δ 24 99 
2 MeCN K3PO4 Δ 24 99 
3 dioxane K3PO4 Δ 24 99 
4 dioxane Cs2CO3 Δ 24 99 
5 MeCN t-BuOK Δ 24 70 
6 MeCN NaH r.t. to Δ 3,5 0 
7 MeCN NaH r.t. 24 50 
 
In summary, no base promoted migration of the N-7 allylic double bond was observed for the 
N-Boc protected compound 112. Therefore our attention switched to the investigation of how 
the rearrangement of 6-iodopurine 49d could be achieved. However, the treatment of 49b or 
49d with various bases did not lead to the migration of the double bond (Scheme 4.19). 
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Scheme 4.19 Reagents and conditions: K2CO3, Cs2CO3 or K3PO4, MeCN, Δ, 24 h. 
 
We then turned to an alternative strategy and chose to study transition metal induced 
rearrangements.130 There are few known examples, describing the metal induced 
rearrangement of the N-allyl group in aromatic compounds and nitrogen containing 
heterocycles.131-136 However, application of this method on the N-allyl purines was not 
reported so far. Consequently, we chose to explore the rearrangement of 49d (Scheme 4.20) 
with catalyst RuClH(CO)(PPh3)3.137,138 This particular Ru catalyst was chosen for its known 
ability to rearrange N-allyl group attached to the endocyclic nitrogen.134,139-141  
 
Scheme 4.20 Reagents and conditions: see Table 4.3. 
 
Initial attempts to migrate the N-allyl double bond in compound 49d were carried out 
in refluxing toluene.134 Limited solubility of 49d in toluene caused very low conversion as 
well as partial substrate decomposition (Table 4.3, entries 1-3). Switching the solvents to 
either THF or DCM resolved the solubility problem. Upon these conditions, the 
rearrangement took place. Nevertheless, the reaction was still somewhat sluggish, giving 
approximately 10% conversion towards the desired intermediate 117d (Table 4.3, entries 4-6).  
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Table 4.3 Rearrangement screening with RuClH(CO)(PPh3)3 
Entry Solv. cat. 
[%] 
T 
[qC] 
Time [h] Conv. 
[%]a 
Note 
1 Toluene 5% 120 2 6  
2 Toluene 5% 120 24 n.d Decomposition 
3 Toluene 5% ∆ 24 16 Partial decomposition 
4 THF 5% 76 24 ~10  
5 DCM 5% ∆ 24 ~10  
6 THF 5% 76 72 ~10  
7 DCE 5% ∆ 12 30 Chlorination 
8 DCE 5% 110 24 16 Partial decomposition, Chlorination 
9 DCE 5% ∆ 24 50 Chlorination, 20% yield of 117b 
10 DCE 10% ∆ 72 50 Chlorination 
11 dioxane 5% ∆ 72 n.d. Decomposition 
aDetermined by 1H NMR of the crude product. 
 
When the reaction was carried out in DCE, the isomerisation progress was slightly higher 
(Table 4.3, entries 7-10). However, an unexpected phenomenon was also observed. The 
combination of RuClH(CO)(PPh3)3 in DCE caused unwanted halogen exchange of the 6-
iodine from iododopurine 49d forming the undesired 6-chloro-7-(prop-1-en-1-yl)-7H-purine 
(117b) (Scheme 4.21). Even though RuClH(CO)(PPh3)3 contains a chloride atom, the catalyst 
cannot be the only source of chlorination. The product 117b was isolated in 20% yield, which 
exceeded the stoichiometric amount of the catalyst in the reaction mixture (Scheme 4.21, 
Table 4.3, entry 9). When 49d was refluxed in DCE in absence of the catalyst, the 
chlorination did not take place. Therefore the catalyst itself was identified as the chlorination 
initiator with DCE as a chlorine source.  
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Scheme 4.21 Reagents and conditions: (a) RuClH(CO)(PPh3)3, DCE, ∆, 24h; (b) DCE Δ, 24 h. 
Several successful rearrangements of allylic double bonds with the Grubbs II catalyst 
are reported.142-144 Hence, we also tried to achieve the rearrangement of 49d using this 
catalyst. However, no rearrangement was observed, and the halogen exchange occurred 
almost exclusively (Scheme 4.22). This generally excluded halogenated solvents from 
consideration. 
 
Scheme 4.22 Reagents and conditions: (a) Grubbs II, DCE, ∆, 24h. 
We then tried to perform the rearrangement in refluxing dioxane (Table 4.3, entry 11). 
Following the reaction by TLC indicated promising progress within the first 48 h of the 
reaction. Regrettably, after 72 h, before the reaction could reach completion, decomposition 
of 49d occurred. Considering the sluggish reaction performance, we decided to explore, 
whether the reaction process could be more efficient under microwave irradiation conditions. 
We prepared a set of experiments in test scale and followed the reaction progress by 1H NMR 
(Scheme 4.23, Table 4.4) no products were isolated.  
 
Scheme 4.23 Reagents and conditions: see Table 4.4, microwave irradiation, dioxane.  
The results presented in Table 4.3 indicated, that successful migration takes place only at 
elevated temperature. Thus, we first performed screening for the optimal reaction temperature 
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(Table 4.4, entries 1-5). As starting point we chose the reaction temperature close to the 
boiling point of dioxane (Table 4.4, entry 1), 1 hour reaction time and 5% catalyst loading. 
The reaction temperature was raised by 10 ºC for each entry. The most promising conversion 
was achieved at 130 °C. Additional increase of the reaction temperature up to 140 °C did not 
lead to further improvement. At this point, we decided to increase the catalyst loading to 10%, 
which resulted in 90% conversion (Table 4.4, entry 6). The last step was to extend the 
reaction time up to 3 hours, which gave slightly higher conversion as well (Table 4.4, entry 
7). 
 
Table 4.4 Microwave assisted catalytic double bond migration of 49d by RuClH(CO)(PPh3)3 
Entry cat. [%] Time [h] T [°C] Conv. [%]a 
1 5 1 100 24 
2 5 1 110 24 
3 5 1 120 46 
4 5 1 130 75 
5 5 1 140 60 
6 10 1 130 90 
7 10 3 130 93 
aDetermined by 1H NMR of the crude product. 
 
Based on these results, the suitable reaction temperature, time and catalyst 
concentration were determined. The experiment was successfully reproduced on a preparative 
scale and the desired rearranged product 117d was isolated with high yield as a 50:50 mixture 
of E/Z isomers (Scheme 4.24, Table 4.5, entry 1). Taking into consideration that the 
rearrangement is taking place at around 130 ºC, we also attempted this reaction in refluxing 
xylenes. To our delight, the isomerisation occurred with the same efficiency. This allowed us 
to perform the migration using convenient standard techniques without microwave irradiation 
(Table 4.5, entry 2). Overall, there is one minor drawback as the rearrangement was always 
followed by minor halogen exchange. As mentioned before, this is caused by the catalyst 
itself, resulting in contamination of the final product 117d by 10% of the unwanted chloro 
analog 117b. When we tried to decrease the catalyst loading to 5%, the conversion dropped 
noticeably (Table 4.5, entry 3). An alternative chlorine free catalyst, RhH(CO)(PPh3)3 was 
also employed on this substrate, but the conversion to the propenylpurine 117d was only 8% 
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(Table 4.5, entry 4).  On the other hand, despite the chlorination, the rearrangement was 
performed on a preparative scale with satisfactory results (Table 4.5, entries 1 and 2). 
Therefore, we decided to move forward and finally employ this method in the synthetic 
pathway.  
 
 
Scheme 4.24 Reagents and conditions: (a) see Table 4.5. 
Table 4.5 Conditions for rearrangement of 49d 
Entry Catalyst Conditions 
Conv. 
[%]a 
Yield 
[%]b 
1 10% RuClH(CO)(PPh3)3 dioxane, microwave, 130 ºC, 3h 95 74c 
2 10% RuClH(CO)(PPh3)3 xylenes, Δ, 3h 90 73c 
3 5% RuClH(CO)(PPh3)3 xylenes, Δ, 3h 68 n.d. 
4 10% RhH(CO)(PPh3)3 xylenes, Δ, 3h 8 n.d. 
aDetermined by 1H NMR of the crude product; bIsolated yield; cCalculated yield of 117d, was isolated together 
with minor amounts of 117b. 
 
The designed isomerisation conditions were also applied on the N-Boc protected 112. 
Treatment of 112 with RuClH(CO)(PPh3)3 gave no selective rearrangement and low 
conversion. Both N-allylic double bonds were isomerized giving a complex mixture of 
rearranged isomers, which were not successfully separated (Scheme 4.25). 
 
 
Scheme 4.25 Reagents and conditions: (a) 10% RuClH(CO)(PPh3)3, xylenes, Δ, 3 h. 
Chapter 4 
 
 
63 
 
The general rearrangement of N-allyl purines was further investigated. The background of the 
rearrangement methodology, mechanisms as well as the scope and limitation study with N-
allyl purines is discussed in the following chapter. 
4.2.4 Application of the double bond migration and C-N coupling in the 
synthesis towards asmarines 
After designing the conditions for N-allyllic double bond isomerisation and C-N bond 
formation, we decided to approach the model synthesis with tert-butyl allylcarbamate (77d) 
(Scheme 4.26). Compound 49d was rearranged to 117d. Intermediate 117d containing 10% of 
the chloro-analogue 117b was then subjected to coupling reaction with tert-butyl 
allylcarbamate (77d). This reaction gave good yield of product 73 as a 50:50 mixture of E/Z 
isomers. The unwanted chloro analogue 117b does not take part in the C-N coupling and was 
separated from the product 73 using flash chromatography. The RCM with 73 led to the 
previously reported18 asmarine analog 74.  While only the Z-isomer of 73 was employed in 
previous synthesis,18 the important outcome of this experiment is that both E- and Z-isomers 
underwent the RCM successfully, yielding product 74.  
 
Scheme 4.26 Reagents and conditions: (a) 10% RuClH(CO)(PPh3)3, xylenes, ∆, 3h; (b) allylcarbamate 77d,  
CuI, 1,10-phenanthroline, Cs2CO3, dioxane, ∆, 2 days; (c) 5% Hoveyda-Grubbs II, DCE, ∆, 1.5 h. 
Regrettably, when we tried to introduce the α-substituted tert-butyl allyl carbamates 77a-b 
(Scheme 4.27), the results were not satisfactory. Using more substituted carbamates 77, the 
copper mediated coupling with 117d did to take place and side reactions started to occur 
instead. The coupling did probably not occur due to the sterical hindrance caused by 
additional α-substitution on amides 77a-b. As experienced before, the reactivity in coupling 
can drop significantly with increasing sterical hindrance of the coupling partners.119  
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Scheme 4.27 (a) CuI, 1,10-phenanthroline, Cs2CO3, dioxane, ∆, 24 h; (b) CuI, 1,10-phenanthroline, K3PO4, 
dioxane, ∆, 24 h, (c) CuI, 1,10-phenanthroline, K3PO4, DMF, ∆, 24 h. 
tert-Butyl allyl carbamates 77a-b showed reasonable stability upon the given conditions and 
were recovered from the reaction mixture in the range of 70-80%. In contrast to this, substrate 
117d formed a mixture of unwanted by-products. The MS ESI spectra analysis revealed that 
trace amounts of the desired product 67a were formed. The dimer 116 was also observed. 
Importantly, the most intensive molecular ion observed in the MS ESI spectra corresponded 
to the probable product 121 (Figure 4.2). This homocoupled product 121 could be formed by 
a copper mediated Ullman reaction.145 The Ullmann reaction can become a competitive 
process, when the rate of the C-N coupling is too slow.110 In addition, similar dimerisation of 
the 6-iodo purines using copper catalyst was reported recently.36 
 
Figure 4.2 Possible product from Ulmann reaction with 117d. 
In order to initiate the coupling, we increased the reaction temperature using reflux in 
DMF.120,146 Nevertheless, no coupling occurred and a complex mixture of by-products was 
formed. The desired product 67a was not observed in this case.  
4.2.5 N-protection experiments 
Realizing that the C-N bond formation cannot easily be achieved in the fashion 
described above, we decided to investigate the N-protection possibility once more. Taking 
advantage of the previously developed double bond migration, we prepared the E/Z-isomers 
of 6-chloro-7-(prop-1-en-1-yl)-7H-purine (117b). Subsequently, intermediate 117b was 
treated with allylamine 45d or the ammonium salt 78a. This allowed easy access to the N-
Chapter 4 
 
 
65 
 
propenyl purines 1 and 46a, with no need to perform time demanding K2CO3 promoted 
isomerisation (Section 3.2.3, page 38). Both products were obtained as E/Z-isomers in good 
overall yield (Scheme 4.28). 
 
 
Scheme 4.28 Reagents and conditions: (a) 10% RuClH(CO)(PPh3)3, xylenes, ∆, 3h; (b) allyl amine (45d),  
DIPEA, n-BuOH, Δ, 2 h; (c) allyl ammonium salt 78a,  DIPEA, n-BuOH, Δ, 48 h. 
At first we investigated, if the secondary amine 1 can be protected via protonation 
with p-toluenesulfonic acid. The resulting salt could then be cyclised under RCM conditions. 
Successful olefin metathesis with amines which were protected in this manner is known.81 
The salt of 1 and p-TsOH was successfully formed as judged by 1H NMR.  Nevertheless, 
when the resulting salt 122 was subjected to RCM conditions, no cyclised product 123 was 
observed even after 24 h (Scheme 4.29).  
 
 
Scheme 4.29 Reagents and conditions: (a) anhydrous p-TSAH, DCM, 30 min;81 (b) 5% Hoveyda-Grubbs II, 
DCE, ∆, 24 h.  
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In view of the previous application of acetyl as the protecting group in the RCM,147,148 
the conversion of the secondary amines into acetamides was also considered. Formation of the 
acetamide could prevent coordination of the N6-nitrogen to the metathesis catalyst and RCM 
could take place (see also Section 3.1.1, page 28). N-Propenyl purine 1 was N-protected 
earlier using Boc anhydride (see Section 3.1.2, page 30). Hence, we decided to use the acetic 
anhydride. Once again we had to face the inactivity of the secondary amine 46a. No 
conversion to acetamide 125 was achieved following the literature conditions,149 even after 
extended reaction time (Scheme 4.30). Furthermore, the conditions which were used for the 
protection of 1 with Boc anhydride,18 were attempted using acetic anhydride instead. This 
attempt resulted in no visible conversion (Scheme 4.30). 
 
Scheme 4.30 Reagents and conditions: (a) acetic anhydride, 5% DMAP, pyridine;149 (b) acetic anhydride, 1eq. 
DMAP, pyridine.18 
We furthermore evaluated the application of the benzyl carbamate (Cbz) protecting 
group. The Cbz group is often employed for amine protection prior to RCM.83,150-152 
Compared to the Boc group, the Cbz group is less bulky, which could facilitate its 
introduction to the sterically hindered amines 1 and 46a. Moreover, it is usually introduced 
using benzyl chloroformate, which might be more reactive with the secondary amine 1 or 46a 
than Boc2O. Several literature conditions were investigated, but no promising outcome was 
achieved in any of the experiments (Scheme 4.31, Table 4.6). Test reactions with 
triethylamine and DMAP153 (Table 4.6, entry 1) or with a stronger base (NaH)154 (Table 4.6, 
entry 2) did not show any visible progress as judged by TLC and the starting material 46a was 
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recovered to major extent. Using Na2CO3 in aqueous MeOH155 led to a complex mixture of 
products. No traces of the desired intermediate 126a were observed (Table 4.6, entry 3). 
 
Scheme 4.31 Reagents and conditions: (a) benzylchloroformate, see Table 4.6. 
Table 4.6 N-protection attempts with benzyl chloroformate 
Entry Solv. Cbz-Cla Cat/Base T 
Time 
[h] 
rec 
[%]b 
1153 DMF 2 DMAP/ Et3N r.t. 48 67 
2154 DMF 1.1 NaH 0 ºC to r.t. 17 60 
3155 MeOH/H2O 1.2 Na2CO3 r.t. 1.5 n.d.c 
aEquivalents of benzylchloroformate, bRecovered starting material,cComplex products mixture formed. 
 
Since the N-protection was not successful with benzyl chloroformate, an additional 
approach for Cbz group introduction was attempted. The Rapoport reagent156 is used for the 
Cbz-protection of exocyclic amines in N-heterocycles.156,157 The reagent is easily prepared 
from commercially available chemicals, starting with the reaction of imidazole with 
benzylchloroformate. The N-Cbz-imidazole is then treated with triethyloxonium 
tetrafluoroborate, and the resulting solution of Rapoport reagent is used as prepared for the 
amine protection (Scheme 4.32).156 Regrettably, when 46a was reacted with the Rapoport 
reagent, the outcome was far from our expectations. On one hand we managed to overcome 
the limited reactivity of 46a, since some progress of the reaction was finally observable by 
TLC. On the other hand, the reaction offered only a complex mixture of products.  
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Scheme 4.32 Reagents and conditions: (a) 1) benzylchloroformate, toluene, 0 ºC to r.t., 17 h, 2) Et3OBF4, DCM, 
0 ºC to r.t., 2 h; (b) compound 46a, MeCN, r.t., 72 h. 
The MS ESI spectra of the crude products indicated that decarboxylation of the Rapoport 
reagent occurred during the reaction. However, no traces of the desired protected product 
126a were detected. Based on MS ESI data we assumed the structures of two possible 
products 128a and 129 (Figure 4.3). These were contaminated by an excess of the Rapoport 
reagent and were not successfully obtained in a pure form, even after repeated column 
chromatography. 
 
 
Figure 4.3 The possible outcome from the treatment of 46a with Rapoport reagent. 
The Boc group can be introduced in similar fashion like the Cbz group using an imidazolium 
salt.158 The reagent was prepared in the same way like the Rapoport reagent from imidazole 
and triethyloxonium tetrafluoroborate (Scheme 4.33).156 
 
Scheme 4.33 Reagents and conditions: 1) Boc2O, toluene, 0 ºC to r.t., 17 h, 2) Et3OBF4, DCM, 0 ºC to r.t., 2 h; 
(b) compound 46a, MeCN, r.t., 72 h. 
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This reagent showed much lower reactivity towards 46a compared to the Rapoport reagent. 
No conversion was seen and thus, preparation of the N-protected RCM precursor 67a in this 
fashion was not successful.  
4.3 Conclusion 
A synthetic approach towards the asmarine analogues 47a-c (Scheme 4.1) was 
presented. The possibilities of employing double bond migration and C-N bond formation 
were investigated. From the initial copper catalysed C-N coupling experiments performed 
with purines it was observed, that the C-N coupling does not occur with 7-allyl-6-chloro-7H-
purine (49b). Thus, the conditions for copper mediated C-N coupling were tested and finally 
determined for the iododerivate 49d. The coupling gave the tert-butyl allyl(7-allyl-7H-purin-
6-yl)carbamate (112) in satisfactory yield. Another obstacle in the reaction pathway was 
successfully overcome, when the rearrangement of N-allyl purine 49d using 
RuClH(CO)(PPh3)3 was explored. The development of conditions for the N-allyl purine 
rearrangement opened the application of this method in the asmarine analogues synthesis. 
Moreover, it also offered a unique opportunity for further investigation of the isomerisation in 
this system, as discussed in Chapter 5. The previously tested Ru mediated double bond 
migration and copper catalysed coupling were successfully applied in the synthesis of tert-
butyl allyl(7-(prop-1-en-1-yl)-7H-purin-6-yl)carbamate (73). Most importantly, the metathesis 
reaction performed with the mixture of E/Z-isomers of this precursor gave the previously 
known18 asmarine analogue tert-butyl [1,4]diazepino[1,2,3-gh]purine-10(9H)-carboxylate 
(74) in good yield. Regrettably, the C-N coupling was not achieved using the target α-
substituted N-allyl carbamates 77a-c. Hence the N-protection had to be further explored. 
Regarding the N-protection of compounds 1 and 46a, several approaches were attempted. The 
amine protection via protonation, introduction of acetyl, Cbz and Boc groups or application of 
the Rapoport reagents were not successful in any of the experiments. The limited reactivity as 
well as sterical hindrance of the secondary amines 1 and 46a probably prevented successful 
formation of the N-protected RCM intermediates in those experiments. The successful 
synthesis of the target asmarine analogues 47a-c was not achieved. Further strategies towards 
asmarine total synthesis are currently under investigation in the Gundersen group at the 
University of Oslo. 
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4.4 Future prospects 
There are two apparent complications in our synthetic strategy: the RCM does not take 
place without the N-protection and there are difficulties to accomplish the N-protection itself. 
Even though we tried several different approaches to avoid these obstacles, there are always 
alternative ways which could be investigated in the future. 
 
Scheme 4.34 N-protection prior to RCM. 
First of all, regarding the introduction of different protecting groups (Scheme 4.34), 
there are several alternative reagents159 for each protecting group which can be employed 
(Figure 4.4). 
 
Figure 4.4 Examples of alternative reagents for the introduction of various protecting groups. 
In addition, at the last stage of our investigation we realized that that the unexpected 
product 35 with the N6-benzyl group was observed in the experiments with the Rapoport 
reagent. This compound was neither isolated in a pure form nor in acceptable amount (see 
Figure 4.3). However, the benzylation should be further explored (Scheme 4.35) since there 
are numerous reports82,83,152,160 describing the benzyl as a suitable protecting group for the 
RCM. Moreover, the ring-closing of a benzyl protected allyl amine intermediates, leading to 
7-membered rings, is known as well.161-163  
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Scheme 4.35 Application of the benzyl as a protecting group in the synthesis. 
Should the RCM reaction not lead to the formation of the desired products even after 
successful installation of the N-protection group, performing the RCM in the presence of a 
Lewis acid could be considered. The beneficial effect of the Lewis acids on the progress of 
the RCM was demonstrated in the synthesis of pyrrolidines (Scheme 4.36).164 
 
Scheme 4.36 Reagents and conditions: (a) e.g. Ti(Oi-Pr)4, Ru-catalyst, CH2Cl2, 40 ºC.164 
In our investigation, based on the previous success,18 we tried to employ the Ru-based 
Hoveyda-Grubbs II catalyst. However, the constantly evolving field of the RCM methodology 
offers also other alternatives such as catalysts based on Molybdenum80 (Figure 4.5). 
 
Figure 4.5 Molybdenium based catalyst165 
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Interestingly, the catalysts 69b and 69c were employed in the synthesis of a 7-
membered ring, which is very similar to our case (Scheme 4.37).165 Most importantly, the 
ring-closing step readily occurred with the unprotected secondary amine 134 with high yields. 
Thus, the application of the various Schrock type catalysts could be investigated. 
 
Scheme 4.37 Reagents and conditions: (a) catalyst 69b or 69c, benzene, 55 ºC, 3 to 24 h. 
4.5 Experimental 
(E/Z)-N-allyl-7-(prop-1-enyl)-7H-purin-6-amine (1) 
Allylamine (45d) (6.35 mmol, 0.480 mL) and DIPEA (2.54 mmol, 0.440 mL) were stirred in 
n-BuOH (6.9 mL) at ambient temperature under N2 and 6-chloro-7-(prop-1-en-1-yl)-7H-
purine (117b) (1.27 mmol, 247 mg, E/Z = 75:25) was added. The reaction mixture was 
refluxed for 2 h. The mixture was evaporated in vacuo and purified by flash chromatography 
using MeOH/CH2Cl2 (1:49); yield 231 mg (96%, E/Z = 75:25), yellow solid. Z-isomer: 1H 
NMR (CDCl3, 300 MHz) δ 1.70 (dd, J1 = 7.0 Hz, J2 = 1.8 Hz, 3H, CH3-1), 4.21 (tt, J1 = 5.6 
Hz, J2 = 1.5 Hz, 2H, CH2-3'), 5.17 (m, 3H, =CH2-1' + NH), 5.95 (m, 1H, CH=-2'), 6.16 (m, 
1H, =CH-2), 6.90 (dd, J1 = 7.8 Hz, J2 = 1.8 Hz, 1H, NCH-3), 7.78 (s, 1H, H-8), 8.51 (s, 1H, 
H-2); 13C NMR (CDCl3, 75 MHz) δ 12.4 (CH3-1), 43.1 (CH2-3'), 111.5 (C-5), 116.6 (=CH2-
1'), 122.9 (NCH-3), 131.6 (=CH-2), 134.1 (CH=-2'), 143.6 (C-8), 150.9 (C-6), 153.4 (C-2), 
158.9 (C-4); E-isomer: 1H NMR (CDCl3, 400 MHz) δ 1.96 (dd, J1 = 7.1 Hz, J2 = 1.3 Hz, 3H, 
CH3-1), 4.22-4.28 (m, 2H, CH2-3'), 5.15-5.27 (m, 3H, =CH2-1' + NH), 5.93-6.05 (m, 1H, 
CH=-2'), 6.07-6.21 (m, 1H, =CH-2), 6.97 (dd, J1 = 13.6 Hz, J2 = 1.9 Hz, 1H, NCH-3), 7.88 (s, 
1H, H-8), 8.53 (s, 1H, H-2); 13C NMR (CDCl3, 100 MHz) δ 15.2 (CH3-1), 43.2 (CH2-3'), 
111.0 (C-5), 116.6 (=CH2-1'), 123.2 (NCH-3), 128.9 (=CH-2), 134.2 (CH=-2'), 143.4 (C-8), 
150.7 (C-6), 153.3 (C-2), 159.1 (C-4); MS (EI) m/z (rel. int.) 215/216 (96/20, M+), 200 (100), 
187 (10), 174 (17), 159 (29), 147 (8), 135 (12), 120 (11), 93 (6), 80 (9), 68 (8), 56 (20), 41 
(48) and 28 (18); HRMS (EI) C18H19N5 requires 215.1171, found 215.1163. 
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(S,E/Z)-N-(1-phenylbut-3-en-2-yl)-7-(prop-1-enyl)-7H-purin-6-amine (46a) 
(S)-1-phenylbut-3-en-2-aminium chloride (78a) (3.82 mmol, 702 mg) and DIPEA (10.7 
mmol, 1.8 mL) were stirred in n-BuOH (19 mL) at ambient temperature under N2 for 10 min 
prior to use. Subsequently, 6-chloro-7-(prop-1-en-1-yl)-7H-purine (117b) (3.47 mmol, 675 
mg, E/Z = 75:25) was added and the reaction mixture was refluxed for 48 h. The solvent was 
evaporated in vacuo. The crude product was purified by flash chromatography using 
MeOH/CH2Cl2 (1:49); yield 78 mg (82%, E/Z = 75:25), yellow solid. Z-isomer: 1H NMR 
(CDCl3, 400 MHz) δ 1.53 (dd, J1 = 7.1 Hz, J2 = 1.6 Hz, 3H, CH3-1), 2.94-3.09 (m, 2H, CH2-
4'), 5.01 (bd, J = 7.9 Hz, 1H, NH), 5.08 (d, J = 17.7 Hz, 1H, HA in =CH2-1'), 5.14 (d, J = 10.7 
Hz, 1H, HB in =CH2-1'), 5.23 (m, 1H, CH-3'), 5.90-6.03 (m, 2H, CH=-2' and =CH-2), 6.68 (d, 
J = 7.8 Hz, 1H, NCH-3), 7.14-7.30 (m, 5H, Ph), 7.74 (s, 1H, H-8), 8.52 (s, 1H, H-2); 13C 
NMR (CDCl3, 75 MHz) δ 12.2 (CH3-1), 40.6 (CH2-4'), 52.4 (CH-3'), 111.5 (C-5), 115.1 
(=CH2-1'), 122.7 (NCH-3), 126.8, 128.4 and 129.6 (Ph), 132.0 (=CH-2), 136.8 (Ph), 137.8 
(CH= 2'), 143.4 (C-8), 150.4 (C-6), 153.7 (C-2), 159.2 (C-4); E-isomer: 1H NMR (CDCl3, 400 
MHz) δ 1.78 (dd, J1 = 7.1 Hz, J2 = 1.6 Hz, 3H, CH3-1), 3.00-3.12 (m, 2H, CH2-4'), 4.80 (bd, J 
= 8.0 Hz, 1H, NH), 5.09 (d, J = 17.8 Hz, 1H, HA in =CH2-1'), 5.15 (d, J = 10.5 Hz, 1H, HB in 
=CH2-1'), 5.29 (m, 1H, CH-3'), 5.85-6.03 (m, 2H, CH=-2', =CH-2), 6.67 (d, J = 13.8 Hz, 1H, 
NCH-3), 7.14-7.30 (m, 5H, Ph), 7.82 (s, 1H, H-8), 8.52 (s, 1H, H-2); 13C NMR (CDCl3, 75 
MHz) δ 15.1 (CH3-1), 41.0 (CH2-4'), 52.3 (CH-3'), 110.9 (C-5), 115.0 (=CH2-1'), 123.0 
(NCH-3), 127.0 and 128.4 (Ph), 129.0 (=CH-2), 129.6 and 136.8 (Ph), 137.8 (CH=-2'), 143.3 
(C-8), 150.1 (C-6), 153.6 (C-2), 159.5 (C-4); MS (EI) m/z (rel. int.) 305 (9, M+), 214 (100), 91 
(7), 56 (10); HRMS (EI) C18H19N5 requires 305.1640, found 305.1645. 
7-allyl-6-chloro-7H-purine (49b) 
7-Allyl-6-iodo-7H-purine (49d) (0.17 mmol, 100 mg) and the catalyst Grubbs II (8.5 x 10-3 
mmol, 7.00 mg) were added to the oven-dried reaction vessel. The vessel was sealed with a 
septum and DCE (3 mL) was injected. Subsequently, the septum was replaced by condenser 
and the reaction was refluxed for 24 h. The mixture was filtered through a silica gel pad using 
10 mL of EtOAc as the eluent. The solvent was removed in vacuo and the residue was 
purified by flash chromatography using gradient elution with MeOH/CH2Cl2 (1:20 to 1:19); 
yield 36 mg (80%), pale yellow solid. The spectral data were in good agreement with those 
reported before.52 
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 (E/Z)-tert-Butyl allyl(7-(prop-1-enyl)-7H-purin-6-yl)carbamate (73)  
A resealable tube was charged with a solid reagents, tert-butyl allylcarbamate (77d) (0.700 
mmol, 110 mg), Cs2CO3 (0.490 mmol, 160 mg) and CuI (1.7 x 10-2 mmol, 3.3 mg, 5 mol%). 
Tube was evacuated and backfilled with Ar. 1,10-Phenanthroline (3.5 x 10-2 mmol, 6.3 mg, 10 
mol%), 6-iodo-7-(prop-1-en-1-yl)-7H-purine (117d) (0.35 mmol, 100 mg, E/Z = 45:55) and 
dioxane (2.1 mL) were added. The tube was sealed and the reaction mixture was stirred at 110 
°C for 48 h.  The mixture was filtered through a pad of silica using 15 mL MeOH/CH2Cl2 
(1:9) as the eluent. Solvents were removed in vacuo and the remaining crude product was 
purified using flash chromatography on silica with MeOH/CH2Cl2 (1:99); yield 66 mg (59%, 
E/Z = 45:55), yellow oil. Z-isomer: 1H NMR (CDCl3, 300 MHz) δ 1.43 (s, 9H, t-Bu), 1.60 (d, 
J = 6.1 Hz, 3H, CH3-1), 4.44 (d, J = 5.8 Hz, 2H, CH2-3'), 5.15 (m, 2H, =CH2-1'), 5.78-5.92 
(m, 2H, =CH-2, CH=-2'), 6.71 (d, J = 8.07 Hz, 1H, NCH-3), 8.07 (H-8), 8.88 (H-2); 13C NMR 
(CDCl3, 75 MHz) δ 12.3 (CH3-1), 28.0 (CH3 in t-Bu), 50.8 (CH2-3'), 82.4 (C in t-Bu), 118.4 
(=CH2-1'), 120.4 (C-5), 126.7 (NCH-3), 128.4 (=CH-2), 134.0 (CH=-2'), 147.7 (C-8 and C-6), 
152.5 (C-2), 153.6 (C=O), 162.2 (C-4); E-isomer: 1H NMR (CDCl3, 600 MHz) δ 1.43 (br s, 
9H, t-Bu), 1.87 (d, J = 6.9 Hz, 3H, CH3-1), 4.54 (d, J = 5.8 Hz, 2H, CH2-3'), 5.14-5.21 (m, 
2H, =CH2-1'), 5.89-6.02 (m, 2H, =CH-2, CH=-2'), 6.83 (d, J = 13.3 Hz, 1H, NCH-3), 8.26 (H-
8), 8.92 (H-2); 13C NMR (CDCl3, 150 MHz) δ 14.1 (CH3-1), 28.1 (CH3 in t-Bu), 50.7 (CH2-
3'), 82.3 (C in t-Bu), 118.1 (=CH2-1'), 122.1 (C-5), 123.3 (NCH-3 and =CH-2), 133.5 (CH=-
2'), 146.2 (C-8), 147.4 (C-6), 152.8 (C-2), 152.8 (C=O), 162.6 (C-4); MS (EI) m/z (rel. int.) 
315 (38, M+), 259 (83), 242 (18), 214 (30), 200 (47), 174 (23), 57 (100); HRMS (EI) 
C16H21N5O2 requires 315.1695, found 315.1689. 
tert-Butyl allyl(7-allyl-7H-purin-6-yl)carbamate (112) 
The reaction vessel was charged with a solid reagents, tert-butyl allylcarbamate 77d (1.00 
mmol, 157 mg), Cs2CO3 (0.700 mmol, 228 mg), CuI (2.6 x 10-2 mmol, 5.0 mg, 5 mol%) 1,10-
phenanthroline (5.5 x 10-2 mmol, 10.0 mg, 10 mol%) and 7-allyl-6-iodo-7H-purine (49d) 
(0.500 mmol, 143 mg) under inert atmosphere of glovebox. THF (3.0 mL) was injected 
through the septum. The heterogeneous reaction mixture was refluxed for 48 h. The mixture 
was filtered through a pad of silica eluting with 10 mL of MeOH/CH2Cl2 (1:9). The solvent 
was removed in vacuo. The crude product was purified using flash chromatography on silica 
with gradient elution by MeOH/CH2Cl2 (1:99 to 1:32); yield 89 mg (56%). Spectral data were 
in a good agreement with those reported before.18 
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(1S,2S)-N1,N2-bis(7-((E)-prop-1-enyl)-7H-purin-6-yl)cyclohexane-1,2-diamine (115) 
The solid reagents CuI (4.2 x 10-2 mmol, 0.70 mg), allylcarbamate 77d (0.42 mmol, 66 mg), 
K3PO4 (0.840 mmol, 178 mg) and 7-Allyl-6-chloro-7H-purine (49b) (0.5 mmol, 100 mg) 
were charged in oven-dried reaction tube under inert atmosphere of glovebox. trans-1,2-
Cyklohexanediamine (4.2 x 10-2 mmol, 5.0 μl, 10 mol%) and dioxane (0.5 mL) were injected 
through the resealable cap. The product was isolated using flash chromatography on silica 
with MeOH/CH2Cl2 (1:9); yield 16 mg (99%), yellow solid, mp 113-120 °C. 1H NMR 
(DMSO-d6, 300 MHz) δ 1.27-1.37 (m, 8H, 2x CH3-1 and cyclohexyl), 1.54 (m, 2H, 
cyclohexyl), 1.74 (m, 2H, cyclohexyl), 2.05 (d, J = 13.2 Hz, 2H, cyclohexyl), 4.41 (m, 2H, 2x 
NCH-cyclohexyl), 5.87 (m, 2H, 2x =CH-2), 6.20 (d, J = 7.3 Hz, 2H, 2x NH), 6.88 (dd, J1 = 
8.0 Hz, J2 = 1.9 Hz, 2H, 2x NCH=-3), 8.11 (s, 2H, 2x H-8), 8.32 (s, 2H, 2x H-2); 13C NMR 
(DMSO-d6, 125 MHz) δ 11.6 (CH3-1), 24.6 (CH2-cyclohexyl), 31.8 (CH2-cyclohexyl), 53.4 
(CH-cyclohexyl), 110.4 (C-5), 122.8 (NCH=-3), 127.6 (=CH-2), 144.5 (C-8), 150.5 (C-6), 
152.4 (C-2), 158.5 (C-4); MS (EI) m/z (rel. int.) 430 (44, M+), 255 (100), 226 (24), 215 (14), 
200 (15), 176 (54); HRMS (EI) C22H26N10 requires 430.2342 found 430.2333. 
1-[7-(Prop-2-en-1-yl)-7H-purin-6-yl]-7-propyl-6,7-dihydro-1H-purin-6-one (116) 
The oven-dried reaction ampoule was charged with a solid reagents 7-Allyl-6-chloro-7H-
purine (49b) (0.500 mmol, 100 mg), allylcarbamate 77d (0.60 mmol, 94 mg), Cs2CO3 (0.700 
mmol, 228 mg), CuI (2.5 x 10-2 mmol, 5.0 mg, 1 mol%) and 1,10-phenanthroline (5.5 x 10-2 
mmol, 10.0 mg, 10 mol%) under inert atmosphere of glovebox. Dioxane (1.0 ml) was injected 
through a resealable cap. The cap was closed and the reaction proceeded at 110 °C for 24 h. 
The crude reaction mixture was filtered through a pad of silica using EtOAc. The solvent was 
removed in vacuo. The product was isolated using flash chromatography on silica with 
MeOH/CH2Cl2 (1:20); yield 31 mg (15%), yellow solid, mp 209-212 °C. 1H NMR (CDCl3, 
300 MHz) δ 4.63-4.79 (m, 3H, NCH2-3', HA in =CH2-1'), 4.94-5.10 (m, 3H, HB in =CH2-1', 
NCH2-3), 5.16 (d, J = 17.1 Hz, 1H, HA in =CH2-1), 5.29 (d, J = 10.2 Hz, 1H, HB in =CH2-1), 
5.69 (m, 1H, CH=-2'), 6.03 (m, 1H, CH=-2). 7.97 (s, 1H, H-8), 8.19 (s, 1H, H-2), 8.30 (s, 1H, 
H-8'), 9.09 (s, 1H, H-2'); 13C NMR (CDCl3, 75 MHz) δ 49.4 (NCH2-3), 49.5 (NCH2-3'), 114.2 
(C-5), 119.2 (=CH2-1), 119.3 (=CH2-1'), 121.2 (C-5'), 131.2 (CH=-2), 132.2 (CH=-2'), 141.1 
(C-6'), 144.4 (C-8), 145.3 (C-2), 149.9 (C-8'), 152.8 (C-2'), 153.8 (C-6), 157.5 (C-4), 163.9 
(C-4'); MS (EI) m/z (rel. int.) 334 (100, M+), 333 (30), 319 (6), 306 (8), 215 (19), 199 (6), 176 
(6), 160 (11); HRMS (EI) C16H14N8O requires 334.1291 found 344.1288. 
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6-Chloro-7-(prop-1-en-1-yl)-7H-purine (117b) 
7-Allyl-6-iodo-7H-purine (49d) (0.35 mmol, 100 mg) and catalyst RuClH(CO)(PPh3)3 (1.7 x 
10-3 mmol, 17.0 mg) were added to the oven-dried reaction vessel. The vessel was sealed with 
a septum and DCE (6.00 mL) was injected. The septum was replaced by condenser and the 
reaction was refluxed for 24 h. The heterogeneous mixture was filtered through a silica gel 
pad using 10 mL of EtOAc as the eluent. The solvent was removed in vacuo and the residue 
was purified by flash chromatography using gradient elution with MeOH/CH2Cl2 (1:20 to 
1:19); yield 36 mg (20%), pale yellow solid. For data see Appendix I. compound 5c 
6-Iodo-7-(prop-1-en-1-yl)-7H-purine (117d) 
Microwave assisted double bond migration with RuClH(CO)(PPh3)3 
A 0.5-2 mL vial was oven-dried prior to use and cooled down under inert atmosphere of Ar. 
7-Allyl-6-iodo-7H-purine (49d) (0.17 mmol, 50 mg) and catalyst RuClH(CO)(PPh3)3 (1.7 x 
10-2 mmol, 17 mg) were added. Vial was sealed with a cap with septum and dioxane (3 mL) 
was injected. The reaction proceeded in microwave reactor for 3 h at 130 qC. The reaction 
mixture was filtered through a silica gel pad using 10 mL of EtOAc as the eluent. The solvent 
was removed in vacuo and the residue was purified by flash chromatography using gradient 
elution with MeOH/CH2Cl2 (1:20 to 1:19); yield 36 mg (72%, contained 10% of Chloro-
analog 117b), pale yellow solid. For data see Appendix I. compound 5e. 
(E/Z)-N-allyl-7-(prop-1-enyl)-7H-purin-6-amommonium 4-methylbenzene-1-sulfonate 
(122) 
A solution of anhydrous p-toluenesulfonic acid (0.46 mmol, 80 mg) in CH2Cl2 (1.53 mL) was 
added to a stirred solution of compound 1 (0.46 mmol, 100 mg) in CH2Cl2 (1.53 mL) at room 
temperature. After stirring for 10 min, the turbid mixture became clear. The solvent was 
removed in vacuo and the resulting salt was dried under reduced pressure; yield 180 mg 
(100%), yellow oil. Z-isomer: 1H NMR (CDCl3, 400 MHz) δ 1.56 (d, J = 6.8 Hz, 3H, CH3-1), 
2.33 (s, 3H, OCH3), 4.33-4.35 (m, 2H, CH2-3'), 5.09 (d, J = 10.2 Hz, 1H, HB in =CH2-1'), 
5.19 (d, J = 17.2 Hz, 1H, CHA in =CH2-1'), 5.83-5.93 (m, 1H, CH=-2'), 6.20 (m, 1H, =CH-2), 
7.15 (d, J = 7.8 Hz, Ph), 7.32 (d, J = 7.8 Hz, 1H, NCH-3), 7.77 (d, J = 7.9 Hz, Ph), 7.88 (s, 
1H, H-8), 8.17 (br s, 1H, NH), 8.54 (s, 1H, H-2); 13C NMR (CDCl3, 100 MHz) δ 12.3 (CH3-
1), 21.3 (OCH3), 44.3 (CH2-3'), 111.3 (C-5), 118.0 (=CH2-1'), 122.1 (NCH-3), 125.9 and 
128.9 (Ph), 132.5 (CH=-2'), 132.6 (=CH-2), 140.3 and 141.9 (Ph), 144.7 (C-8), 146.6 (C-2), 
147.8 (C-4), 152.0 (C-6); E-isomer: 1H NMR (CDCl3, 400 MHz) δ 1.88 (d, J = 6.6 Hz, 3H, 
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CH3-1), 2.33 (s, 3H, OCH3), 4.31-4.33 (m, 2H, CH2-3'), 5.09 (d, J = 10.2 Hz, 1H, HB in 
=CH2-1'), 5.19 (d, J = 17.2 Hz, 1H, CHA in =CH2-1'), 5.83-5.93 (m, 1H, CH=-2'), 6.05-6.11 
(m, 1H, =CH-2), 7.15 (d, J = 7.8 Hz, Ph), 7.50 (d, J = 13.4 Hz, 1H, NCH-3), 7.77 (d, J = 7.9 
Hz, Ph), 7.97 (s, 1H, H-8), 8.44 (br s, 1H, NH), 8.50 (s, 1H, H-2); 13C NMR (CDCl3, 100 
MHz) δ 15.1 (CH3-1), 21.3 (OCH3), 44.4 (CH2-3'), 110.7 (C-5), 117.9 (=CH2-1'), 122.6 
(NCH-3), 125.9 and 128.9 (Ph), 130.8 (=CH-2), 132.4 (CH=-2'), 140.3 and 141.9 (Ph), 144.7 
(C-8), 146.3 (C-2), 148.0 (C-4), 151.9 (C-6); MS (ESI) m/z (rel. int.) 216 [M+H]+, 171 
[M+H]+. 
tert-Butyl 1H-imidazole-1-carboxylate (130)  
Imidazole (14.7 mmol, 1.00 g) was stirred in 15 mL of CH2Cl2 at room temperature, until 
completely dissolved. A solution of Boc2O (20.6 mmol, 4.5 g) in 5 mL of CH2Cl2 was added 
dropwise. The mixture was stirred for 15 h and the solvent was removed in vacuo. The crude 
product was purified by flash chromatography on silica gel eluting with EtOAc/Hex (1:6); 
yield 1.96 g (79%), colourless crystals, mp 44-46 °C (Lit166 42-45 °C). Spectral data were in a 
good agreement with those reported before.166  
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Chapter 5  
Rearrangement of N-allyl purines  
5.1 Introduction 
During the course of our work on studying synthetic routes towards asmarines (Chapter 
3 and Chapter 4), we investigated conditions for the rearrangement of the asmarine 
intermediates 49b, 49d and 75a-c. These preliminary results offered a unique possibility for 
the synthesis of N-alkenyl purines. Since there are in general very few convenient synthetic 
routes to N-alkenyl purines, we decided to carry out a further exploration of this methodology. 
Herein, we focused on base- or transition metal complex promoted isomerisations (Scheme 
5.1). Even though the more thermodynamically stable E-isomers of propenyl purines were 
expected as major products, some of the base promoted rearrangements occurred with a 
surprisingly high Z-selectivity. The synthesis of starting materials for this study is described 
in Chapter 2. 
 
 
Scheme 5.1 Example of the rearrangement of the N-9 allyl purine. 
5.1.1 Alkenyl purines 
Alkenyl purines are seldom reported in the literature and in general not easy to 
synthesize. For instance, the vinyl purines can be obtained as a mixture of N-7 and N-9 isomer 
by vinylation of purines with Hg(OAc)2 (Scheme 5.2).167,168  
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Scheme 5.2 Reagents and conditions: (a) Hg(AcO)2, H2SO4/EtOAc, 40 ºC, 3 to 4 days. 
Furthermore, it was recently reported, that the N-7 alkenylated purines can be isolated as the 
only product from the reaction of acetylene carboxylates in the presence of PPh3 (Scheme 
5.3).169  
 
Scheme 5.3 Reagents and condition: (a) 1) PPh3, CH2Cl2, -15 ºC to r.t., 15 min; 2) K2HPO4, 90 ºC, 1 h.169  
In addition, 7-propenyl purine can be quantitavely obtained by selective N-7 allyl 
rearrangement of N6,N-7-diallyladenine 72 as we demonstrated previously (Section 3.1.2 page 
30 and ref. 18) 
Regarding the formation of N-9 alkenyl purines, more examples can be found in the 
literature. Apart from the reaction with vinyl acetate and Hg salts,168 the vinylation can be 
achieved with di- or tetrachloro ethene in HMPA.170 More convenient procedures employ Cu-
promoted alkenylation with boronic acids171 or Michael addition with activated alkynes.172-174 
Furthermore, the alkenyl purines can be synthesised by tandem N-alkylation/elimination 
methods,175-177 or by Horner-Wadsworth-Emmons reactions.178,179 In addition, the ring 
opening of 9-(cyclobutenyl)purines, or reactions of 9-(2,2-diethoxyethyl)purines with malonic 
acid leading to the N-alkenyl formation is known.180 The literature examples of the N-9 
alkenyl purines syntheses are given in the Scheme 5.4. 
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Scheme 5.4 Reagents and conditions: (a) Hg(AcO)2;168 (b) base, HMPA;170 (c) Cu(OAc)2;171 (d) Et3N;172 (e) 
CH3COOH;177 (f) NaH;178 (g) liq. NH3/EtOH;181 (h) malonic acid.180 
Most importantly, the alkenyl purines can be prepared by migration of the allylic 
double bond in the presence of t-BuOK.129,182 The first synthesis of alkenyl purines via double 
bond migration was reported by in 1965.129 
 
Scheme 5.5 Reagents and conditions: (a) t-BuOK, DMSO, 100 ºC, 20 min.129 
 The biological activities of several N-9 alkenyl purines were investigated and the compounds 
displayed anticancer-172,183 and antiviral- properties177,182-184 or kinase inhibiting 
activities.179,185 
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5.1.2 Double bond migration in N-allyl systems 
Isomerisation of N-allyl groups is the important example of reactions in allylic 
systems. Various allylic intermediates (e.g. amines, imines, amides, imides, N-allyl protected 
heterocycles) can be easily converted to the corresponding N-(1-propenyl) or more generally 
N-vinyl products in this fashion (Scheme 5.6).130  
 
 
Scheme 5.6 Double bond migration of the N-allyl group. 
In general, the double bond rearrangement can be induced by various classes of 
reagents130,186 such as acids (e.g. H2SO4, HClO4), bases (e.g. KOH, NaOMe, t-BuOK), metals 
on support (Pd/C, Rh/C, Ru/C) and transition metal complexes (e.g. RuClH(CO)(PPh3)3, 
RuCl2(PPh3)3, RhH(CO)(PPh3)3 and Fe(CO)5. The application of the rearrangement 
methodology includes preparation of amino acid derivatives,131 formation of the precursors 
for the cycloaddition reactions,139,140 removal of the N-allyl protecting group129,134,141,186 or 
synthesis of the nucleoside analogues.132 One of the interesting examples is the synthesis of 
various heterocycles employing a tandem sequence of migration followed by the RCM 
(Scheme 5.7).187,188 
 
Scheme 5.7 Reagents and conditions: (a) Grubbs II, toluene, r.t., 5 h; (b) RuClH(CO)(PPh3)3, toluene, 95 ºC, 2 h; 
(c) Grubbs II, toluene, 45 ºC, 2,5 h; (d) Grubbs II, CHCl3, r.t., 24 h, then 45 ºC, 24 h; (e) RuClH(CO)(PPh3)3, 
toluene, 105 ºC, 24 h; (f) Grubbs II, toluene, 50 ºC, 24 h, r.t. then further Grubbs II, 80 ºC, 24 h.187 
Chapter 5 
 
 
82 
 
5.1.2.1 Reaction mechanism of the base promoted rearrangement 
The mechanistic studies of the base promoted allylic rearrangement were reported 
earlier with various allylic substrates such as but-3-en-2-ylbenzene,189 substituted pent-1-
enes,190 allyl ethers,191,192 or cis-but-2-ene.193 It has been commonly established,194 that the 
base promoted rearrangement occurs via a carbanion formation.189-193 The deprotonation on 
the C-1' of the allyl leads to the π-allyl anion which is stabilised by the base, especially when 
the Q-group is a heteroatom with an electron lone pair available for interaction with the cation 
species (Scheme 5.8).191,192 The proton abstracted from the C-1' is then transferred to the 
carbon C-3'.191,193 
 
Scheme 5.8 Base promoted double bond migration via π-allylic anion. 
5.1.2.2 Mechanism of the rearrangement with transition metal hydrides 
The isomerisation of N-allyl purines was studied with RuClH(CO)(PPh3)3, which 
belongs to the group of metal hydride catalysts.  The rearrangement promoted by this type of 
catalyst occurs via a hydride addition-elimination mechanism.186,195 In the initial phase of the 
catalyst cycle, the metal hydride coordinates to the π-electrons of the allyl group. The 
coordination is then followed by 1,2-addition on the double bond. The metal alkyl 
intermediate may then, by β-hydrogen elimination, form either the desired rearranged product 
or revert to the original metal coordinated olefin (Scheme 5.9).186 
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Scheme 5.9 Hydride addition-elimination mechanism of the allyl rearrangement. 
 
The Ru or Rh mediated rearrangements are usually Z-selective.137,138,196,197 
Nonetheless, if an aromatic ring is present in the molecule, E-selectivity is observed instead. 
The β-hydride elimination is considered to be the key step for the E-selectivity. The transition 
state proposed for this phenomenon showes that the E-stereoselectivity originates from the 
coordination of the Ru atom to the aromatic ring (Scheme 5.10).137,138,196,197 This hypothesis 
was supported by theoretical calculations.138,196 In our case, high E-selectivity of the double 
bond migration of N-allyl purines with RuHCl(CO)(PPh3)3 was also observed. 
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Scheme 5.10 The coordination of the Ru atom with the aryl substituent as a possible reason for the E-selectivity 
of RuClH(CO)(PPh3)3 mediated rearrangement with aromatic substrates.138 
Various transition metal hydrido-complexes such as (HCo(CO)4), (RuClH(CO)(PPh3)3) or 
(PtH(ClO4)(PPh3)3) belong to the class of catalysts that rearranges allyl groups according to 
the addition-elimination mechanism.186 
5.1.2.3 π-Allyl hydride mechanism 
In contrast to transition metal hydride promoted rearrangements, isomerisation 
induced by non-hydrido complexes of Fe or Ir occurs via a π-allyl hydride 
mechanism.186,193,198 The 1,2-addition does not occur in the course of this mechanism. Instead, 
the catalyst forms a π-allyl hydride complex in situ.192,198-200 The hydride is then directly 
migrated via 1,3-hydrogen shift from the C-1' to C-3' through this metal complex intermediate 
(Scheme 5.11). 
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Scheme 5.11 π-allyl hydrido mechanism. 
Typical examples of non-hydrido complexes, isomerising olefins according to the π-allyl 
hydrido mechanism are Fe(CO)5, Fe3(CO)12 or complexes of palladium, such as 
PdCl2(PhCN)2 and the cationic iridium complexes Ir(cod)(PMePh2)2+ PF6- or BF4+.186 The 
possible advantage of the rearrangement by a π-allyl hydrido mechanism was investigated for 
the rearrangement of 2-methylallyl purines (Section 5.2.3) 
5.2 Results and discussion 
5.2.1 Rearrangement of 7-allyl purines 
 
 
Scheme 5.12 Rearrangement of 7-allyl purines. 
A very convenient rearrangement method was discovered, when the compound N,7-
diallyl-7H-purin-6-amine (72) was isomerised under very mild basic conditions, giving the 
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corresponding rearranged product (Z)-N-allyl-7-(prop-1-en-1-yl)-7H-purin-6-amine (1) in 
quantitative yield.18 In general, this type of rearrangement is a rather special phenomenon and 
this was the first known synthesis of a 7-propenyl purine. Furthermore, the migration in this 
case takes place regioselectively on the N-7 allyl chain while the N6-allyl remains intact. 
Above all, the most surprising feature of this isomerisation is the complete Z-selectivity. In 
the current study towards asmarines, we slightly extended the scope of this reaction for the 
substrates 75a-c. The corresponding products 46a-c were obtained in high yield again 
exclusively as the Z-isomers (see page 31, Scheme 3.4 and page 38, Scheme 3.15). 
Subsequently, we performed further investigations of this type of double bond migration 
using 7-allyl purines with various substituents in the C-2 and C-6 position (Scheme 5.12, 
Table 5.1). First of all, to evaluate the importance of the base for this reaction, we refluxed 
adenine 49a in MeCN in the absence of the K2CO3. As expected, the rearrangement did not 
occur (Table 5.1, entry 1). We then applied the K2CO3 mediated rearrangement with all the 
designed substrates. Surprisingly, the rearrangement occurred only with the adenine type of 
derivates 49a and 72 (Table 5.1, entries 2 - 4), while other 7-allylpurines remained unchanged 
under given conditions. In the case of methoxypurine 49e, solvents with higher boiling point 
such as chlorobenzene or dioxane were employed with no success. Consequently, we refluxed 
compound 49e in n-BuOH. In this particular case some migration was achieved, but also with 
an additional replacement of the methoxy group caused by n-BuOH (Table 5.1, entry 9, 
Scheme 5.13). 
  
 
Scheme 5.13 Reagents and conditions: (a) K2CO3, n-BuOH, Δ, 4 days. 
When t-BuOK129 was used for the reaction with adenine 49a, the reaction went to completion 
after 20 minutes at ambient temperature. In contrast to the Z-selectivity with K2CO3, the 
product 117a was obtained with the majority of E-isomer (Table 5.1, entry 3). 
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Table 5.1 Base promoted rearrangement of the 7-allylpurines 
Entry Subst. R2 R6 Method Time [h] 
Conv. 
[%]a E/Z
a Yield [%]b 
1 49a H NH2 MeCN, Δ 96 n.r. – – 
2 49a H NH2 Ac 96 90 >1:99 53, 117a 
3 49a H NH2 Bd 0.30 98 69:31 84, 117a 
4 72 H NH-allyl A 17 100 >1:99 100, 1
e 
5 49b H Cl A 24 n.r. – – 
6 49c NH2 Cl A 96 n.r. – – 
7 49d H I A 24 n.r. _ _ 
8 49e H OMe A 24 n.r.f – – 
9 49e H OMe Ag 96 –h – – 
aFrom 1H NMR of the crude product, after 24 h if otherwise not stated; bIsolated yield; cMethod A: K2CO3, 
MeCN, Δ; dMethod B: t-BuOK, DMSO, r.t.; eTaken from reference 18; fAlso n.r. in dioxane, ' or Ph-Cl, '; gn-
BuOH as solvent; hDouble bond migration took place, but the MeO-group was also partly exchanged with n-
BuO-group (Scheme 5.13). 
 
It can be summarised from these results, that only the purines with a free amino groups were 
successfully rearranged using the mild base (K2CO3) in MeCN. Subsequently, 7-allyl purines 
were subjected to the previously designed isomerisation conditions with RuClH(CO)(PPh3)3 
in refluxing xylenes (see also Section 4.2.3, page 55).  In general, the Ru promoted 
isomerisation occurred with all the N-7 allyl analogues (Table 5.2) and the rearranged 
products were isolated in good yields. In the case of compound 49a the isomerisation required 
an extended reaction time. The product 117a was, despite the good conversion, isolated only 
in moderate yield, which was caused by a challenging separation of 117a from the starting 
material 49a by column chromatography (Table 5.2, entry 1). Low conversion was observed 
in the rearrangement of N,7-diallyl-7H-purin-6-amine (72). The two allyl chains from the 
substrate 72 are in close vicinity and probably prevented the proper addition of the relatively 
bulky RuClH(CO)(PPh3)3 catalyst to the double bond. This may have caused the slow 
progress of the reaction. Regrettably, the product from this reaction was not isolated pure 
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(Table 5.2, entry 2). The isomerisation of 9-allyl-6-iodo-9H-purine (49d) was followed by a 
minor halogen exchange (Table 5.2, entry 5), as discussed previously (see Section 4.2.3, page 
58). 
 
Table 5.2 Rearrangement of the 7-allylpurines with RuClH(CO)(PPh3)3 
Entry Subst. R2 R6 Method Time [h] 
Conv. 
[%]a E/Z
a Yield [%]b 
1 49a H NH2 Cc 24 80 38:62 38, 117a 
2 72 H NH-
allyl 
C 24 40 28:72 –d 
3 49b H Cl C 3 99 75:25 76, 117b 
4 49c NH2 Cl C 3 89 74:26 78, 117c 
5 49d H I C 3 90 50:50 73, 117de 
6 49e H OMe C 3 97 81:19 87, 117e 
aFrom 1H NMR of the crude product, after 24 h if otherwise not stated; bIsolated yield. cRuClH(CO)(PPh3)3, 
xylenes, Δ; dNot isolated in pure form; eCalculated yield of 49d, was isolated together with minor amounts of 49b. 
 
5.2.2 Rearrangement of 9-allyl purines 
 
 
Scheme 5.14 Rearrangement of 9-allyl purines. 
In the first report regarding the formation of N-propenyl purines, the N-9 allyl adenine 
48a was isomerised using t-BuOK in DMSO at 100 ºC.129 Since no E/Z selectivity was 
mentioned, we decided to examine this procedure. The method proved to be easily 
reproducible giving the E-isomer 151a as the major product (Table 5.3 entry 1). Furthermore, 
we found that the reaction is equally efficient at ambient temperature (Table 5.3, entry 2). 
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When t-BuOK was exchanged with K2CO3, the rearrangement was significantly slower, 
leading to only 40% conversion after 8 days (Table 5.3, entry 3). In contrast to the efficient 
method with t-BuOK, none of the N-9 allylpurines were rearranged using K2CO3 in refluxing 
MeCN. Based on the previous report,18 we therefore performed the reaction with substrates 
48a, 165 and 48e in refluxing n-BuOH instead of MeCN. This brought satisfactory results 
with adenines 48a and 165. The rearrangement was Z-selective, although to a much lower 
extent (Table 5.3, entry 5 and 7) compared to 7-allylpurines (see Table 5.1). Interestingly, 
only the N-9 allyl chain was isomerised in the case of the substrate 165. In a similar manner 
like before, the methoxy group from the substrate 48e was replaced by the butoxy group when 
48e was treated with K2CO3 in n-BuOH (Table 5.3, entry 13). 6-Chloro purine 48b is not 
compatible with t-BuOK and a complex mixture of products was formed (Table 5.3, entry 9). 
 
Table 5.3 Base promoted rearrangement of the 9-allylpurines 
Entry Subst. R2 R6 Methoda Time [h] Conv. [%]b E/Zb Yield [%]c 
1 48a H NH2 Bd 0.30 >99 95:5 92, 151ae 
2 48a H NH2 B 0.30 >99 93:7 93, 151a 
3 48a H NH2 Ad 8 days 40 16:84 _ 
4 48a H NH2 A 96 n.r. – – 
5 48a H NH2 Af  96 92 37:63 69, 151a 
6 165 H NH-
allyl 
A 96 n.r. – – 
7 165 H NH-
allyl 
Af 48 90 35:65 89, 166 
8 48b H Cl A 24 n.r. – – 
9 48b H Cl B 0.30 _g _ _ 
10 48c NH2 Cl A 24 n.r. – – 
11 48d H I A 24 n.r. – – 
12 48e H OMe A 24 n.r.h – – 
13 48e H OMe Af 96 –i – – 
aMethods A and B are defined in Table 5.1; bFrom 1H NMR of the crude product; cIsolated yield; dperformed at 
100 oC; eperformed according to ref. 51; fn-BuOH as solvent; gA complex mixture formed, chloride exchanged 
with t-BuO; hAlso n.r. in dioxane, ' or Ph-Cl, '; iDouble bond migration took place, but the methoxy group was 
also partly exchanged with butoxy. 
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 All the 9-allyl purines were readily isomerised to 9-propenyl purines, when exposed to 
catalytic amounts of RuClH(CO)(PPh3)3 (Table 5.4). The range of the E-selectivity (83-86%) 
was slightly higher than for the corresponding N-7 isomers. When the N,9-diallyl-9H-purin-6-
amine (165) was treated with the Ru catalyst, both allyl chains were rearranged as judged 
from the 1H NMR of the crude product (Table 5.4, entry 2). Nevertheless, limited stability of 
the probable product 167 did not allow a successful isolation (Scheme 5.15).  
 
 
Scheme 5.15 Reagents and conditions: (a) cat. RuClH(CO)(PPh3)3, xylenes, Δ, 3 h. 
When the iodide 48d was reacted with RuClH(CO)(PPh3)3, a minor halogen exchange 
occurred (Table 5.4, entry 5). Apart from the product 167, all the other N-9 propenyl purines 
were obtained in good yields (Table 5.4).  
 
Table 5.4 Rearrangement of the 9-allylpurines with RuClH(CO)(PPh3)3 
Entry Subst. R2 R6 Methoda Time [h] Conv. [%]b E/Zb Yield [%]c 
1 48a H NH2 C 3 98 86:14 84, 151a 
2 165 H NH-allyl C 3 >99
d –d –d 
3 48b H Cl C 3 97 86:14 85, 151b 
4 48c NH2 Cl C 3 97 83:17 76, 151c 
5 48d H I C 3 95 84:16 77, 151de 
6 48e H OMe C 3 97 83:17 86, 151e 
aMethod C is defined in Table 5.2; bFrom 1H NMR of the crude product; cIsolated yield; dNMR indicated that 
compound 167 (E/Z 35:65) was formed, but the compound was not isolated in pure form; eCalculated yield of 
48d, was isolated together with minor amounts of 48b. 
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In addition, we investigated the rearrangement of 3-allyl-3H-purin-6-amine 59 (Scheme 5.16). 
This substrate seems to be generally less suitable for the rearrangement, and the reaction with 
K2CO3 in MeCN did not give any isomerisation. To our surprise, the Ru promoted 
rearrangement did not occur to any extent either with this substrate. When the adenine 59 was 
treated with K2CO3 in refluxing n-BuOH, a significant deallylation was observed after 24 
hours. The ratio between product 168, substrate 59 and adenine 6a was determined by 1H 
NMR to be 49:25:26. Finally, the rearrangement using t-BuOK in DMSO gave the product 
168 as a predominant E-isomer (E/Z 85:15) although in limited yield.  
 
 
Scheme 5.16 Reagents and conditions: (a) K2CO3, MeCN, Δ, 24 h; (b) cat. RuClH(CO)(PPh3)3, xylenes, Δ, 3 h; 
(c) K2CO3, n-BuOH, Δ, 24 h; (d) t-BuOK, DMSO, 100 ºC, 20 min. 
5.2.3 Substitution on allyl C-2' position 
After investigating of the rearrangement with purines bearing the simple N-7 and N-9 
allyl group, we moved forward to purines with an additional substitution on the N-allyl chain. 
In the first place, we explored the influence of the methyl group on the double bond migration 
using 2-methylallyl derivates (Scheme 5.17). 
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Scheme 5.17 Example of the rearrangement with N-2-methylallyl purine. 
The tendency to undergo the rearrangement was initially tested under basic conditions (Table 
5.5). No rearrangement was observed with the 6-chlorosubstrates (Table 5.5, entries 1 and 4). 
In the case of the adenine substrates 62b and 63b, the base promoted rearrangement led to the 
desired products. The N-7 allyladenine 63b was conveniently isomerised with K2CO3 in 
refluxing MeCN, giving high yield of the product 170b. Nevertheless, for the rearrangement 
of the corresponding N-9 isomer, more forcing conditions were required.  Even though the 
isomerisation was carried out under microwave irradiation, the conversion only reached 50% 
after 16 hours (Table 5.5, entry 6). Refluxing the compound 62b in n-BuOH gave a 
comparable result (Table 5.5, entry 7). Regrettably, the product and the starting material were 
not successfully separated. The most efficient method for the 2-methylallyl adenines 62b and 
63b was the application of t-BuOK. First of all, using the literature conditions,129 we 
rearranged the adenine 62b in DMSO at 100 ºC (Table 5.5, entry 8). Moreover, the reaction 
was also performed with the same efficiency at ambient temperature. The substrates 62b and 
63b were converted almost quantitatively to the corresponding products. The products 169b 
and 170b were obtained with high yield (Table 5.5, entries 3 and 9). 
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Table 5.5 Base promoted rearrangement of the 2-methyl-allylpurines 
Entry Subst. R6 Methoda Time [h] Conv. [%]b  
Yield 
[%]c 
1 63a Cl A 24 n.r. _ 
2 63b NH2 A 48 94 90, 170b 
3 63b NH2 B 0.30 92 74, 170b 
4 62a Cl A 48 n.r. _ 
5 62b NH2 A 48 n.r. _ 
6 62b NH2 Ad  16 50 _ 
7 62b NH2 Ae 72 43 _ 
8 62b NH2 Bf 0.30 93 90, 169b 
9 62b NH2 B 0.30 93 87, 169b 
aMethods A and B are defined in Table 5.1; bFrom 1H NMR of the crude product; cIsolated yield; 
d200 oC, microwave cond.; en-BuOH as solvent; fPerformed at 100 oC. 
 
Application of RuClH(CO)(PPh3)3 was much less efficient. Almost no migration was 
observed with all of the substrates under standard conditions (Table 5.6) even with extended 
reaction time. In addition, the almost identical polarity of the starting material and the product 
did not allow successful separation by column chromatography or by recrystallisation in any 
of the cases.  
 
Table 5.6 2-methylallyl purines under standard conditions with RuClH(CO)(PPh3)3 
Entry Subst. R6 Methoda 
Time 
[h] 
Conv. 
[%]b 
Yield [%]c 
1 63a Cl C 3 n.r. _ 
2 63a Cl C 24 6 _ 
3 63b NH2 C 24 n.r. _ 
4 62a Cl C 48 21 _ 
5 62b NH2 C 24 11 – 
6 62b NH2 C 48 6 _ 
aMethod C is defined in Table 5.2; bFrom 1H NMR of the crude product; cIsolated yield. 
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After this lack of success using the standard Ru promoted procedure, we tried to adjust the 
rearrangement conditions for 2-methylallyl chloropurines 62a and 63a, which could not be 
rearranged using t-BuOK. We performed a set of test reactions with the 6-chloro purine 62a 
(Scheme 5.18, Table 5.7). Initially, we attempted to improve the conversion using the 
microwave irradiation (Table 5.7, entry 1). Nonetheless, even increasing the reaction 
temperature up to 175 ºC did not give any significant improvement of the process (Table 5.7, 
entries 2-4). Thus, the catalyst loading was increased (Table 5.7, entry 5) or the reaction was 
carried out with a continuous addition of the catalyst over 96 hours (Table 5.7, entry 6). 
Regrettably, in both cases the reactions did not bring about satisfactory results. 
 
 
 
Scheme 5.18 Reagents and conditions: see Table 5.7. 
  
Table 5.7 Attempts for the improvement of the isomerisation of 62a with RuClH(CO)(PPh3)3 
Entry 
Ru catalyst  
loading [%] 
solvent 
Temp. 
[ºC] 
Time 
[h] 
Conv. [%]a 
to 169a  
1 10 dioxane 130b 3 9 
2 10 dioxane 150 to 160b,c 5 8 
3 10 dioxane 175b 3,5 10 
4 10 xylenes 175 24 10 
5 20 xylenes Δ 96 44 
6 30d xylenes Δ 96 36 
aFrom 1H NMR of the crude product; bMicrowave irradiation used; c3 h at 150 ºC and 2 
h at 160 ºC; dStarted with 5% catalyst loading, 5% catalyst was added every 16 hours. 
 
A possible answer for the significant drop in the reactivity of 2-methyl allyl substrates could 
be found in the rearrangement mechanism (Scheme 5.19). The crucial point of the Ru-hydride 
addition-elimination mechanism is the 1,2-addition step (Section 5.1.2.2). For the 
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rearrangement to take place, the ruthenium catalyst needs to be attached to the C-2' position. 
However, in the case of the 2-methyl allyl group, this C-2' position is occupied by the methyl 
group, which would complicate this addition. For this reason, the catalyst is most probably 
adding to the less hindered carbon C-3' instead. If the catalyst is added to the C-3', the 
catalytic cycle will lead back to the starting 2-methylallyl group after the β-hydride 
elimination, which in turn would explain a low overall conversion. 
 
Scheme 5.19 C-2' substituted allyl group in the hydride mechanism. 
Facing severe problems with the Ru mediated migration we decided to explore other possible 
alternatives. Exchanging the ruthenium with the similar rhodium catalyst did not lead to any 
isomerisation (Scheme 5.20). We then switched our attention to the rearrangement carried out 
with Fe(CO)5. 
 
Scheme 5.20 Reagents and conditions: (a) cat. RhH(CO)(PPh3)3, xylenes, Δ, 24 h. 
This reagent was considered since the isomerisation with Fe(CO)5 takes place via the π-allyl 
hydride mechanism198 (Section 5.1.2.3). Ideally, the methyl group on the carbon C-2' should 
not interfere with the reaction progress (Scheme 5.21). Furthermore, a similar case of 
rearrangement of the 2-methylallyl group is reported in the literature.131,200 
Chapter 5 
 
 
96 
 
 
Scheme 5.21 Possible π-allyl hydrido mechanism for the rearrangement of the 2-methyl allyl group. 
Several test reactions were carried out with the chloropurine 62a. Following the literature 
procedure, we started with 0.2 or 1 equivalent of Fe(CO)5 (Table 5.8, entries 1 and 2) in 
refluxing xylenes.131,200 Despite the low conversion, we also observed that a notable amount 
of Fe(CO)5 is evaporated from the reaction mixture during reflux. Due to the volatility of 
Fe(CO)5 we decided to perform the reaction in a sealed tube. When the reaction mixture was 
heated at 140 ºC for 24 hours, the desired product 169a was detected by 1H NMR (Table 5.8, 
entry 4). The progress was further improved with longer reaction time or by increasing the 
amount of Fe(CO)5 in the reaction mixture (Table 5.8, entries 5 and 7). Unfortunately, when 
we further raised the loading of Fe(CO)5, a partial reductive dehalogenation of 62a to 171 was 
observed (Table 5.8, entry 6). Reductive dehalogenation using Fe(CO)5 is known, but usually 
takes place only in protic solvents.201-203 The formation of the reduced product 171 was not 
prevented using dry and degassed solvents and working under the inert atmosphere of a 
glovebox. Furthermore we realised, that while varying different parameters of the procedure 
(Table 5.8, entries 5 and 7-12), the outcome of the reaction was very similar. The conversion 
to the product 169a varied from 42-65%. We deducted two possible reasons for this low 
conversion. Either the catalyst is thermally unstable, which was suggested before,192 or the 
reaction reaches an equilibrium between the starting material and the rearranged product. 
Fe(CO)5 is also known to be photosensitive, however, running the reaction in the dark did not 
lead to any significant improvement (Table 5.8, entry 11). Subsequently, a simple experiment 
was performed to investigate the reason for the limited conversion. A mixture of purine 62a 
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and 169a was used as a starting material. This forced the reaction to progress further (Table 
5.8, entry 12) and also indicated, that the reason of the low conversion is actually the thermal 
stability of Fe(CO)5 and not the establishment of an equilibrium in the reaction. At this point 
we simply carried out the reaction with continuous addition of fresh Fe(CO)5 over 24 hours. 
Finally, the isomerisation gave appreciable conversion and the desired product was 
successfully isolated in reasonable yield (Table 5.8, entry 13). 
 
 
 
Scheme 5.22 Reagents and conditions: (a) Fe(CO)5, see Table 5.8. 
Table 5.8 Screening for the rearrangement conditions with Fe(CO)5 
Entry 
Eq. 
Fe(CO)5 
T 
[ºC]a 
Time 
[h] 
Conversion [%]b Yieldc  
[%]169a 62a 169a 171 
1 0.2 Δ 24 87 13 _ _ 
2 1 Δ 24 65 35 _ _ 
3 1 100 24 100 _ _ _ 
4 1 140 24 75 25 _ _ 
5 1 140 48 58 42 _ _ 
6 2 120 24 88 4 8 _ 
7 2 140 24 45 55 _ _ 
8 4 140 24 39 58 3 _ 
9 2 140 48 41 55 4 _ 
10 2 150 24 43 57 8 16 
11 2 140d 24 52 45 3 _ 
12e 2 140 24 22 65 13 _ 
13 4f 140 24 23 71 6 48 
aSealed tube used if not stated otherwise; bFrom 1H NMR of the crude product; cIsolated yield; 
dPerformed in the dark; eStarted with 42:58 mixture of 62a to 169a; f0.5 eq. was added every 6 
hours.  
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To compare the reactivity, we also performed the Fe(CO)5 mediated rearrangement 
using the allylic purine 48b with an unsubstituted allyl chain (Table 5.9, Scheme 5.23). The 
isomerisation with the N-allyl purine 48b occurred more readily. The product 151b was 
obtained in high yield with 2 eq. of Fe(CO)5 after 3 hours. Thus, the continuous addition of 
Fe(CO)5 was not required in this case. Further increase of the reaction time up to 24 h gave a 
slightly higher conversion as well as improved yield (Table 5.9, entry 2). This rearrangement 
gave the E-isomer of 151b in high excess. Minor traces of the reduced starting material 172 
were also observed. 
 
 
Scheme 5.23 Reagents and conditions: (a) Fe(CO)5, see Table 5.9. 
Table 5.9 Double bond migration of 48b with Fe(CO)5  
Entry 
Eq. 
Fe(CO)5 
T [ºC]a 
Time 
[h] 
Conversion [%]b Yield [%]c 
151b 48b 151b 172 
1 2 140 ºC 3 8 91 1 88, E/Z 85:15 
2 2 140 ºC 24 3 95 2 93, E/Z 87:13 
aSealed tube; bFrom 1H NMR of the crude product; cIsolated yield. 
 
When we treated the N-7 isomers 49b and 63a with Fe(CO)5, the outcome was somewhat 
surprising. The rearrangement did not occur and only a reduction of the starting material was 
observed (Scheme 5.24). The hydride species formed in situ from Fe(CO)5 (Scheme 5.11 and 
Scheme 5.21) probably reacted with the chloride in the C-6 position. Both dechlorinated 
products 173 and 174 were successfully isolated and characterised (Table 5.10). The 
increased tendency of the N-7 purines to undergo reductive dehalogenation compared to N-9 
isomers, was noted before in a study of Negishi couplings.66 
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Scheme 5.24 Reagents and conditions: (a) Fe(CO)5, see Table 5.10. 
 
 
Table 5.10 Reductive dehalogenation of N-7 allyl purines with Fe(CO)5 
Entry Subst. R 
Eq. 
Fe(CO)5 
T 
[ºC]a 
Time 
[h] 
Conversion [%]b Yieldc 
[%] s.m. migr. Red. 
1 49b H 2 140 3 70 _ 30 25, 173 
2 63a Me 2 140 24 33 _ 66 32, 174 
aSealed tube; bFrom 1H NMR of the crude product; cIsolated yield. 
 
In summary, the application of Fe(CO)5 does not seem to be suitable for the 6-chloro-
N-7 allyl purines, while the corresponding N-9 isomers 48b and 62a were successfully 
rearranged by this method and the products were obtained in good yields. 
 
5.2.4 Substitution on allyl C-3' position 
N-allyl C-3' substituted purines was the last class of substrates, we investigated in the 
isomerisation study. In most of the cases, the use of Ru or the base promoted rearrangement 
of the C-3' substituted allyl purines lead to a mixture of the desired N-propenyl purines and 
the purines bearing N-homoallylic side chain (Scheme 5.25). Generally, isolating the N-
propenyl products was appreciably easier compared to the C-2' substituted analogues and so 
even in cases with low conversion, the products 175 and 176 were isolated in pure form. 
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Scheme 5.25 The rearrangement with C-3' substituted allylpurines. 
All the substrates did not react at all under the mild basic conditions with K2CO3 in 
MeCN (data not shown). The adenine derivates which cannot undergo nucleophilic 
substitution were also treated with K2CO3 in refluxing n-BuOH (Table 5.11).  The 
rearrangement occurred only in the case of substrate 60f. Despite the low conversion, the 
product 176f was successfully isolated (Table 5.11, entry 13). Interestingly, even though we 
started the reaction with 60f as a pure E-isomer, the starting material was recovered as a 96:4 
E/Z mixture (Table 5.11, entry 13).  This indicates that the deprotonation by K2CO3 took 
place, but was not followed by the migration to any significant extent (Scheme 5.26). 
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Scheme 5.26 Possible explanation of the E/Z isomerisation of the compound 60f. 
We then approached more forcing conditions with t-BuOK in DMSO at room temperature, 
which gave generally less than 20% conversion for the compounds 61d, 61e, 61f, 60d, 60e 
and 60f. Most importantly, the deallylation leading to adenine 6a was observed in all of the 
cases. If the reaction mixture was heated to 100 ºC, the deallylation occurred almost 
quantitatively within 20 minutes. The isomerisation of the substrates 61d and 60d occurred 
with higher Z-selectivity (Table 5.11, entries 2 and 9). The substrates 61e and 60e were 
rearranged only to the homoallylic analogues 65d and 64d (Table 5.11, entry 5 and 12). The 
fact that the N-alkenyl products 176e and 175e were not observed in this case gives an 
indication, that after the deprotonation at CH2 the rearrangement did not occur and the 
deallylation took place instead. When the deprotonation took place on the other side of the 
double bond, the terminal alkenes could be formed (Table 5.11, entries 2, 5, 9 and 12). In 
connection with this, the highest degree of allyl chain cleavage was observed with the 
cinnamylaldehyde 61f and 60f, which can only be deprotonated at CH2 (Table 5.11, entry 7 
and 14). In the case of t-BuOK mediated rearrangement of 61d and 60d, the formation of the 
terminal alkenes was also detected by 1H NMR of the crude product mixture (Table 5.11, 
entries 2 and 9).  In general, the terminal alkenes 64 and 65 were not obtained in pure form 
and were identified by a comparison with the spectral data of the reference compounds. The 
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reference compounds were prepared by N-alkylation with the corresponding homoallylic 
halides (Section 2.2.3, page 22). 
 
Table 5.11 C-3' substituted allylpurines under basic conditions 
Entry 
Starting 
material 
R1 R2 R6 Methoda 
Time 
[h] 
Conversion [%]b  
Yield [%] 
175  or 
176 (E/Z)d 
E/Z 
recovered 
60 or 61 
60 
or 
61 
175 
or 
176 
64 
or 
65 
6ac 
1 61d H Me NH2 Ae 24 >99 n.d.f n.d. n.d. – >99:1 
2 61d H Me NH2 B 0.30 83 13 1 3 12 (34:66) >99:1 
3 61e Me Me NH2 Ae 72 >99 n.d. n.d. n.d. – – 
4 61e Me Me NH2 Ag 7 54 n.d. n.d. 46 – – 
5 61e Me Me NH2 B 0.30 94 n.d. 5 1 – – 
6 61f H Ph NH2 Ae 24 >99 n.d. – n.d. – >99:1 
7 61f H Ph NH2 B 0.30 78 2 – 20 – (>99:1) >99:1 
8 60d H Me NH2 Ae 72 >99 n.d. n.d. n.d. – >99:1 
9 60d H Me NH2 B 0.30 79 16 1 4 9 (54:46)h >99:1 
10 60e Me Me NH2 Ae 72 >99 n.d. n.d. n.d. – – 
11 60e Me Me NH2 Ag 3 >99 n.d. n.d. n.d. – – 
12 60e Me Me NH2 B 0.30 71 n.d. 18 11 – – 
13 60f H Ph NH2 Ae 72 89 11 – n.d. 10 (80:20) 96:4 
14 60f H Ph NH2 B 0.30 54 n.d. – 46 – >99:1 
aMethods A and B are defined in Table 5.1; bFrom 1H NMR of the crude product; cFormation of adenine 6a; dIsolated 
yield; en-BuOH as solvent; fnot detected; g200 oC, microwave cond.;hRatio from 1H NMR of the crude product 40:60.  
 
All the C-3' substituted allylpurines were slightly more reactive compared to the substrates 
with 2-methylallyl purines, when treated with RuClH(CO)(PPh3)3. On the other hand, the 
conversion was still much lower compared to the substrates 48 and 49 with unsubstituted allyl 
moiety. Generally, all the rearrangements gave the N-propenyl purines as major products with 
high E-selectivity. The terminal alkenes, when possible to form, were also observed. In 
addition, the isomerisation of the starting material from the E-isomer to Z-isomer occurred. 
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Table 5.12 C-3' substituted allylpurines with RuClH(CO)(PPh3)3 
Entry 
Starting 
material 
R1 R2 R6 Methoda 
Time 
[h] 
Conversion [%]b 
Yield [%] 175 
or 176 (E/Z)c 
E/Z 
recovered 
60 or 61 
60 
or 
61 
175 
or 
176 
64 
or 
65 
1 61a H Me Cl C 24 58 32 11 28 (85:15) 79:21 
2 61d H Me NH2 C 24 75 22 3 20 (67:33) 88:12 
3 61b Me Me Cl C 24 >99 n.d. n.d. – – 
4 61e Me Me NH2 C 24 >99 n.d. n.d. – – 
5 61c H Ph Cl C 24 91 9 – – (>99:1) 95:5 
6 61f H Ph NH2 C 24 >99 n.d. – – >99:1 
7 60a H Me Cl C 24 47 46 7 42 (90:10) 79:21 
8 60d H Me NH2 C 24 47 48 5 35 (>99:1)d 84:16 
9 60b Me Me Cl C 24 82 8 10 – (>99:1) – 
10 60e Me Me NH2 C 24 93 3 4 – (>99:1) – 
11 60c H Ph Cl C 24 87 13 – – (>99:1) 97:3 
12 60f H Ph NH2 C 48 88 12 – 9 (>99:1) 97:3 
aMethod C is defined in Table 5.2; bFrom 1H NMR of the crude product; cIsolated yield; dRatio from 1H NMR of the 
crude product 87:13. 
 
The low reactivity of the C-3' substituted substrates could once again be explained by the 
hydride addition-elimination mechanism.186 For the simple, unsubstituted N-allyl, there are 
only two possible outcomes from the 1,2-addition step. Either the Ru catalyst is attached to 
the C-2', which leads to the desired N-propenyl group formation, or the Ru catalyst is 
connected to the C-3' and then the β-hydride elimination will direct the reaction back to the 
original N-allyl group (see Scheme 5.9). In contrast to this, if an additional substituent (e.g. 
methyl group) is present in the C-3' and the Ru is attached to the C-3' position as well, the β-
hydride elimination can also lead to the formation of N-homoallyl group. Most importantly, 
all the isomers have a possibility to enter the catalytic cycle again. Thus, a mixture of several 
different isomers could be expected as the outcome of this type of reaction. 
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Scheme 5.27 Possible outcome from the Ru mediated rearrangement of the C-3' substituted allyl group. 
5.3 Summary and conclusions 
The rearrangement of N-allyl purines under basic conditions was explored. Only N-7-
allyl adenines were successfully rearranged by K2CO3 in refluxing MeCN. This K2CO3 
rearrangement occurred with a remarkably high Z-selectivity. Most of the other substrates 
were unreactive with K2CO3 or required solvents with higher boiling point for the 
rearrangement to take place. The cleavage of the allyl chain and formation of homoallyl 
derivates was observed, when certain substituted allylpurines were treated with strong base (t-
BuOK). 
 
The RuClH(CO)(PPh3)3 catalysed isomerisation of precursors with a simple N-allyl chain was 
found to be a suitable method for the synthesis of N-propenyl purines. The Ru promoted 
rearrangements occurred with high E-selectivity. The efficiency of the rearrangement with 
RuClH(CO)(PPh3)3 significantly dropped with increasing substitution pattern around the 
allylic double bond. The reasons for the limited reactivity of the purines with 2-methyl allyl 
and C-3' substituted allyls were proposed based on the hydride addition-elimination 
mechanism. In the case of the rearrangement of the C-3' substituted substrates, the E- to Z-
isomerisation of the starting material itself as well as the formation of homoallyl purines was 
observed. For the 2-methyl-allyl purines an alternative method employing Fe(CO)5 was 
successfully explored. 
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5.4 Future prospects 
The complete Z-selectivity in the K2CO3 mediated rearrangement of compounds 72 and 
75a-c is a very interesting feature (see page 31, Scheme 3.4 and page 38, Scheme 3.15) since 
the Z-isomers are generally regarded as the less thermodynamically stable products. A similar 
example of N-allyl rearrangement is not reported in the literature. Bearing in mind that base 
promoted allylic rearrangements occurs via carbanion formation (Section 5.1.2.1), we can 
assume that the whole process has to start with deprotonation of the CH2 group in the C-1' 
position (Scheme 5.28).  
 
Scheme 5.28 Deprotonation by K2CO3 in N-7 allyl purine 49. 
Thus, performing the reaction with chloro purine 49b, bearing the electronegative chlorine 
atom in the C-6 position, should lead to the isomerisation as well. However, the reaction did 
not take place at all in this case (Scheme 5.29). In opposition to this, considering the 
remaining results presented in the Table 5.1, the rearrangement occurs readily when an 
electron donating primary and secondary amino group is present in the C-6 position. 
Therefore it seems that this kind of isomerisation is specific only for the 7-allyl adenines with 
exchangeable NH protons. On top of that, replacing the exchangeable proton in the 6-NHR 
group with methyl or Boc group leads to a drop in the reactivity in K2CO3 mediated 
isomerisations. This was observed in the case of compound 11818 and 112 (Section 4.2.3, 
page 57). The corresponding N-9 isomers were also rearranged using K2CO3 but in this case 
the reaction required higher temperatures and the E/Z selectivity dropped significantly 
(Scheme 5.29). 
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Scheme 5.29 Reagents and conditions: (a) K2CO3, MeCN, Δ; (b) K2CO3, n-BuOH, Δ, (c) see Table 4.2 page 57. 
Therefore, the rearrangement in the case of 7-allyl adenines could be facilitated by the 
presence of the 6-NHR group. 
 
Scheme 5.30 Possible facilitation of the K2CO3 rearrangement by 6-NHR group. 
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This hypothesis offers an explanation of the increased reactivity of the N-7 allyl adenines in 
the reaction with mild K2CO3. However, the significantly high Z-selectivity still needs to be 
explained. The fact that only one single Z-isomer was obtained from this rearrangement 
indicates, that the reaction occurs in a way which prevents a formation of the E-isomer. If we 
accept that the interaction of the amino group with protons from the N-7 allyl C-1' group is 
the cause of the intramolecular rearrangement, then this rearrangement could occur via two 
possible 6-membered cyclic transition states. The twisted boat conformation of the transition 
state would lead to the E-isomer. More importantly, if the transition state has a chair 
conformation, the outcome of the reaction will be the Z-isomer, which was observed in our 
case. Hence this theory could be investigated for example by theoretical calculations. 
 
 
Scheme 5.31 Proposed 6-membered cyclic transition state for the K2CO3 mediated rearrangement of 7-allyl 
adenines. 
In addition, a deuterium labeled experiment could be performed in order to have more insight 
into this system (Scheme 5.32).  
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Scheme 5.32 Reagents and conditions: (a) K2CO3, MeCN, Δ. 
Performing the experiment with compound 72 and deuterium labeled isomer 177 in a 1:1 
mixture would reveal, whether we are dealing with the intramolecular isomerisation or not. 
Moreover, if the C-6 amino group interacts with the N-7 allyl chain and the rearrangement 
takes place via the proposed 6-membered cyclic mechanism, the deuterium should be 
introduced to the C-3' position of the N-propenyl chain in the product 178. Both 1 and 177 
should then be easily distinguishable by 1H NMR of the crude products. The evaluation of the 
proposed hypothesis would be a suitable starting point for a following study in the field of N-
allyl isomerisations. 
 
Furthermore, a broad scope of base mediated isomerisation conditions was explored 
e.g. with 9-allyl-9H-purin-6-amine (48a) (Table 5.3, page 89). When the adenine 48a was 
refluxed with K2CO3 in n-BuOH for 3 days, the expected product 151a was obtained as a 
mixture of E/Z isomers. Using t-BuOK in DMSO at 100 qC or at room temperature resulted in 
a high yield of product 151a, which was formed almost exclusively as the E-isomer. In 
addition, in the course of a recent study on functionalization of the purine 8-position via 8-
purinyl anions204 it was reported, that treating 48a with LDA at -78 qC in THF resulted in a 
formation of the product 151a as well, but with high Z-selectivity in this case (Scheme 5.33). 
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Scheme 5.33 Reagents and condition: (a) t-BuOK, DMSO, 100 qC, 20 min.;  (b) K2CO2, n-BuOH, Δ, 4 days; (c) 
5eq. LDA, THF, -78 qC, 1 h. 
A similar outcome from reaction was observed when the 9-allyl-6-(piperidin-1-yl)-9H-purine 
was treated with LDA.205 The deprotonation took place in N-allyl as well as in the C-8 
position and the rearranged product was obtained as pure Z-isomer (Scheme 5.34).  
 
Scheme 5.34 Reagents and conditions: (a) 1) LDA, THF, -78 qC, 1 h, 2) C2Cl6, -78 qC, 15 min.; (b) 1) LDA, 
THF, -78 qC, 1 h, 2) NH4Cl, -78 qC, 1 h. 
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 The low reaction temperature indicates a kinetic control of the process and the high Z-
selectivity in this case could be explained again by possible π-allylic carbanion formation. 
Theoretical calculations showed a possible intermediate with the lithium atom coordinated to 
the allylic moiety and stabilized further by coordination to the nitrogen N-3 of the purine.205 
This  Similarly high Z-selectivity of the LDA induced rearrangement was reported in a study 
of isomerisation of allyl ethers.206  
 
Scheme 5.35 Rearrangement of the 9-allyl purines by LDA via π-allylic anion as a possible explanation of the Z-
selectivity. 
In summary, the examples discussed above illustrate that E/Z selectivity of the 
isomerisation could potentially be controlled. Nevertheless, the general guidelines for the E/Z 
selectivity cannot yet be concluded, since too many variable parameters in the reaction 
conditions were used so far. Hence, the future study of N-allyl purines could be focused on 
the influence of different bases, solvents as well as temperatures on the E/Z selectivity of the 
N-allyl rearrangement.  
5.5 Experimental 
6-Butoxy-7-(prop-1-en-1-yl)-7H-purine (164) 
K2CO3 (2.24 mmol, 310 mg) and 7-allyl-6-methoxy-7H-purine 49e (0.45 mmol, 85 mg) were 
stirred in refluxing n-BuOH for 4 days. The mixture was cooled down and filtered. The 
solvent was removed in vacuo and the product was isolated using flash chromatography on 
silica gel with gradient elution by MeOH/CH2Cl2 (1:32 to 1:16); yield 29 mg (24%), yellow 
solid. Z-isomer: 1H NMR (CDCl3, 300 MHz) Gt, J = 7.3 Hz, 3H, CH3 in Bu-
m, 2H, CH2 in Bu-1.84 (m, 5H, CH2 in Bu and CH3-1), 4.51 (t,  J = 6.6 Hz, 2H, 
OCH2), 5.71-5.81 (m, 1H, =CH-2), 6.92 (dd, J1 = 8.6 Hz, J2 = 1.8 Hz, 1H, NCH-3), 8.06 (s, 
1H, H-8), 8.59 (s, 1H, H-2)13C NMR (CDCl3, 75 MHz) G12.6 (CH3-1), 13.7 (CH3 in Bu), 
19.2 (CH2 in Bu), 30.2 (CH2 in Bu), 66.8 (OCH2), 112.6 (C-5), 122.2 (=CH-2), 123.1 (NCH-
3), 144.7 (C-8), 152.5 (C-2), 157.4 (C-6), 161.1 (C-4); E-isomer: 1H NMR (CDCl3, 300 MHz) 
Gt, J = 7.2 Hz, 3H, CH3 in Bu-m, 2H, CH2 in Bu-1.88 (m, 5H, CH2 
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in Bu and CH3-1), 4.54 (t,  J = 6.6 Hz, 2H, OCH2), 5.95-6.06 (m, 1H, =CH-2), 7.09 (dd, J1 = 
14.2 Hz,  J2 = 1.8 Hz, 1H, NCH-3), 8.19 (s, 1H, H-8), 8.57 (s, 1H, H-2)13C NMR (CDCl3, 75 
MHz) G(CH3 in Bu), 15.1 (CH3-1), 19.2 (CH2 in Bu), 30.7 (CH2 in Bu), 66.8 (OCH2), 
111.9 (C-5), 118.9 (=CH-2), 123.6 (NCH-3), 142.2 (C-8), 152.3 (C-2), 157.2 (C-6), 161.4 (C-
4); MS (EI) m/z (rel. int.) 232 (23, M+), 202 (6), 189 (6), 176 (100), 149 (22); HRMS (EI) 
C12H16N4O requires 232.1324, found 232.1322. 
7-Allyl-7H-purine (173) 
The reaction tube was charged with FeCO5 (0.51 mmol, 66 μL) and 7-Allyl-6-chloro-7H-
purine (49b) (0.26 mmol, 50 mg) under inert atmosphere of glovebox. Xylenes (2.1 ml) were 
injected through septum on resealable cap. The cap was closed and the mixture was stirred at 
138 ºC for 24 h. The resulting thick mixture was filtered through a silica pad using 15 mL 
MeOH/CH2Cl2 (1:9) as the eluent. The filtrate was concentrated in vacuo. The final product 
was isolated using flash chromatography on silica with MeOH/CH2Cl2 (1:9); yield 10 mg 
(25%), beige solid, mp 71-72 °C. 1H NMR (CDCl3, 400 MHz) δ 4.88 (d, J = 5.8 Hz, 2H, 
NCH2), 5.31 (d, J = 17.0 Hz, 1H, HA in =CH2), 5.31 (d, J = 10.5 Hz, 1H, HB in =CH2), 6.02 
(m, 1H, CH=), 8.21 (s, 1H, H-8), 8.93 (s, 1H, H-6), 9.14 (H-2); 13C NMR (CDCl3, 100 MHz) 
δ 48.6 (NCH2), 120.5 (=CH2), 125.3 (C-5), 130.6 (CH=), 140.2 (C-6), 147.8 (C-8), 153.4 (C-
2), 161.0 (C-4); MS (EI) m/z (rel. int.) 160 (100, M+), 133 (14), 160 (11), 79 (6); HRMS (EI) 
C8H8N4 requires 160.0749, found 160.0751. 
7-(2-Methylallyl)-7H-purine (174) 
6-Chloro-7-(2-methylallyl)-7H-purine (63a) (0.24 mmol, 50 mg) and FeCO5 (0.48 mmol, 64 
μL) were added to the reaction tube under inert atmosphere of glovebox. Xylenes (1.9 ml) 
were added through septum on resealable cap. The cap was sealed and the mixture was stirred 
at 138 ºC for 24 h. The resulting thick solution was filtered through a silica pad using 15 mL 
MeOH/CH2Cl2 (1:9) as the eluent. The filtrate was concentrated in vacuo. The final product 
was isolated using flash chromatography on silica with MeOH/CH2Cl2 (1:9); yield 14 mg 
(32%), beige solid, mp 95-97 oC. 1H NMR (CDCl3, 400 MHz) G1.70 (s, 3H, CH3), 4.78 (s, 
2H, NCH2), 4.93 (s, 1H, HA in =CH2), 5.09 (s, 1H, HB in =CH2), 8.19 (s, 1H, H-8), 8.91 (s, 
1H, H-6), 9.13 (s, 1H, H-2)13C NMR (CDCl3, 100 MHz) G19.6 (CH3), 52.4 (NCH2), 115.7 
(=CH2), 125.4 (C-5), 138.4 (C(CH2)CH3), 140.3 (C-6), 148.1 (C-8), 153.4 (C-2), 160.9 (C-4); 
MS (EI) m/z (rel. int.) 174 (100, M+), 159 (24), 133 (20), 120 (9), 106 (11); HRMS (EI) 
C9H10N4 requires 174.0905, found 174.0902.
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